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ABSTRACT
A Novel Correction for the Adjusted Box-Pierce Test — New Risk Factors for Emergency
Department Return Visits within 72 hours for Children with Respiratory Conditions —
General Pediatric Model for Understanding and Predicting Prolonged Length of Stay
by Sidy Danioko
This thesis represents the results of three research projects that underline the breadth and
depth of my interests.
Firstly, I devoted some efforts to the well-known Box-Pierce goodness-of-fit tests for time
series models which has been an important research topic over the last few decades. All
previously proposed tests are focused on changes of the test statistics. Instead, I adopted a
different approach that takes the best performing test and modifying the rejection region.
Thus, I developed a semiparametric correction of the Adjusted Box-Pierce test that attains
the best I error rates for all sample sizes and lags and outperforms all previous global time
series goodness-of-fit approaches.
Secondly, I aimed to study and identify novel risk factors significantly associated with 72-
hour return visits to emergency departments. We queried data consisting of 185,000 ED
visits of patients less than 18 years in the United States using the Cerner® Health Facts
Database. A nested mixed-effects logistic regression model to provide statistical inference
on associated risk factors was built, and a representative set of machine learning algorithms
for our predictive modeling task was selected. New respiratory conditions including acute
bronchiolitis, pneumonia, and asthma were identified as risk factors for return visits to ED.
Thirdly, I ambitioned to design and implement a comprehensive study to identify new clinical
and demographic factors associated with prolonged length of stay (> two weeks) among
pediatric patients (aged 18 years and under) in a number of free-standing pediatric and mixed
VI
medical facilities. We implemented a mixed effect model to assess the statistical significance
and effect sizes of age, race/ethnicity, number of medications, medical family history, presence
of infection agents (fungi, bacteria, virus), cancer diagnoses, and other conditions as well as
some clinical variables. A stochastic gradient model was also implemented for prediction.
From the mixed-effects model, 11 main effect predictors were found to be significantly and
statistically associated with an increase in the odds of prolonged length of stay. The area
under the operator characteristic curve (AUROC) for the mixed-effects model was 0.887
(0.885, 0.889) and the extreme gradient boosting model attained an AUROC of 0.931 (0.930,
0.933).
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1 Introduction
Currently, data accumulation is accelerating and touching every domain of life. For example,
in physics time series arises quite often when studying very dynamic complex systems. In
engineering, electricians are always engaged in better understanding the time dependent as-
pects of power flow over a fixed interval of time. In medicine, doctors daily or weekly conduct
lab tests or other screening techniques on patients. In social sciences, the population growth
rates are regularly measured in the hope of prescribing trends and design recommendations
for the future. In finance and economics, the daily, weekly, and monthly prices of stocks are
constantly collected for studies leading to better investment plans. In the industry world,
some scientists observe the time evolution of the densities of plasma.
Data come in many forms including structured, unstructured, semi-structured, discrete,
continuous, high dimensional, to just name a few. Due to the existence of various types of
data and the multitude of research questions that can be posed, understanding and modeling
have been attracting various communities of researchers and practitioners. Particularly
important has been the presence of the notion of data and the science behind data (data
science) at the intersection of all the above-cited data related activities. Arguably, data
science has been viewed as a study domain that lies at the intersection of math and statistical
knowledge, hacking skills, and very broad and deep expertise. From all the difficulties of
generating a considerable amount of data to a world submerged by data, the field of data
science has evolved in several directions and matured in numerous aspects. With time and the
abundance of data (structured and unstructured), data science has gradually become one of
the intellectually stimulating research areas within companies, universities, and governments.
In fact, finding sound mathematical theory and computational algorithms have produced
unprecedented success stories. Nevertheless, uncountable practical applications and active
research topics continue to emerge. Thus, it is still acceptable to say that data science has
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not yet reached a completely mature stage.
I have devoted parts of my doctoral work to both extending theoretical results and inves-
tigating medical data in the hope of gaining understanding, insight, and knowledge with
respect to situations that are inflecting serious psychological and financial burdens on pa-
tients and hospitals as well. This dissertation consists of four parts. Part I is devoted to
the introduction. Part II is focused to creating a novel correction to the adjusted version
of the Ljung-Box statistic, one of the most popular time series goodness-of-fit diagnostic
test statistics. Part III addresses the risk factors of 72-hour return visits attributable to
the most common respiratory conditions and the contribution of non-respiratory comorbid
conditions/diseases. Part IV is concerned with designing and implementing a comprehensive
study to identify new clinical and demographic factors associated with prolonged length of
stay (> two weeks) among pediatric patients (aged 18 years and under) in a number of
free-standing pediatric and mixed medical facilities.
2
2 A Novel Correction for the Adjusted
Box-Pierce Test
The Box-Jenkins algorithm is a general systematic approach for model checking of a time se-
ries model. Examples of the approach can be found in [1], [2] and , [3]. A well-fitting model
produces residuals that are free of correlation. Thus standard goodness-of-fit approaches are
in essence global tests for absence of correlation among estimated residuals. Accordingly,
many statistical techniques have been designed to assess the absence of correlation among
the time series model residuals.
Following classical notation, let {Xt} be an observed time series generated by a stationary and
invertible ARMA(p,q) process φ(B)Xt = θ(B)εt, where φ(B) and θ(B) are the autoregressive
and moving average characteristic polynomial and BkXt = Xt−k is the backshift operator.
The desired parameters, φi and θi are estimated using maximum likelihood or least squares
methods to obtain φ̂i and θ̂i, the residuals are calculated via ε̂t = θ̂
−1(B)φ̂(B)Xt and the
sample auto-correlation coefficients are in turn obtained from r̂k =
∑n
t=k+1 ε̂tε̂t−k/
∑n
t=1 ε̂
2
t .
In recent years, many techniques have been employed to test the global hypothesis of all
autocorrelations up to a certain lag, H0 : r1 = r2 = ... = rm = 0. In general, these
techniques are designed as weighted sums of squares of the estimated autocorrelations and
they can produce misleading conclusions due to deviations from the asymptotic limiting
distribution in moderate size samples [4] , [5], [6]. Thus, a new and more robust test is
proposed in this research that attains precise type I error rates for all sample sizes.
The history of portmanteau tests traces its roots back to the Box-Pierce diagnostic test
defined as [6], [7] :
QBP = n
m∑
k=1
r̂2k, (2.1)
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where n, m, and r̂k represent the sample size, number of lags being tested and the sam-
ple auto-correlation of order k of the residuals respectively. The authors showed that the
asymptotic distribution of QBP is approximately χ
2(m-p-q) but considerable deviations for
moderate sample sizes have been observed [7], [8], [9]. That deficiency entails imperfections
of type I error rates and prompted the design of a weighted and improved versions of the
test. In their stimulation studies, Ray and Xiaolou focused on investigating the type I errors
in the χ2m setting [4]. They remarked that Box-Pierce rejects too often because of the fact
that the test statistic is too small.
Ljung and Box were the first ones to propose a design that assigns larger weights to residuals
estimated with more data [7]:
QLB = n(n+ 2)
m∑
k=1
r̂2k
n− k
= n
m∑
k=1
n+ 2
n− k
r̂2k. (2.2)
The Box-Pierce and Ljung-Box tests are asymptotically equivalent. The Ljung-Box test has
been shown to overcorrect in moderate samples [4]. They also realized that Ljung-Box
inflates the test statistic using a variance estimate of the residuals. They further showed
that on moderate sized data, QLB rejects too often because the test statistic is too small.
Li and McLeod refined the QBP test [9] by proposing the following statistic,
QLB = QBP +
m(m+ 1)
2n
=
m(m+ 1)
2n
+ n
m∑
k=1
r̂k, (2.3)
This approach only corrects the mean of the Box-Pierce statistic and consequently fails to
properly adjust the type I error rates.
Monti proposed a portmanteau test based on the residual partial autocorrelations [10]. The
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test is defined as,
QM = n(n+ 2)
m∑
k=1
π̂2k
n− k
, (2.4)
Monti showed via simulations that the performance of QM is comparable to that QLB [10].
In addition, he concluded that in certain scenarios, QLB outperfroms QM .
Peña and Rodŕiguez proposed a test based on a different measure of dependence of the
residual autocorrelations, [11],
D = n(1− |R̂m|1/m), (2.5)
where
R̃m =

1 r̂1 . . . r̂m
r̂1 1 . . . r̂m−1
...
...
. . .
...
r̂m r̂m−1 . . . 1

(2.6)
In their work, the authors showed that under particular conditions, their test greatly outper-
formed QLB test. Furthermore, they demonstrated that the test had an advantage over the
McLeod and Li’s test regardless of sample size. However, the convergence of the asymptotic
distribution of the test developed by Peña and Rodŕiguez is very slow [12].
Fisher proposed new weighted versions of the Box-Pierce and Monti’s tests, the Q statistic:
[5],
Q̃WL = n(n+ 2)
m∑
k=1
m− k + 1
m(n− k)
r̂2k, (2.7)
and
Q̃WM = n(n+ 2)
m∑
k=1
m− k + 1
m(n− k)
π̂2k, (2.8)
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A comparison simulation study by [13] showed that for small sample size and m values QWL
performs better than QLB . For moderate sample sized data, they also found that QWL does
better than QLB and QWM outperforms QM .
To remedy some of the shortcomings of all previously existing tests, Kan and Wang proposed
a new modification of the portmanteau test, widely called the adjusted Box-Pierce test [4].
They defined their statistic as,
QaBP = m +
√
2m
V ar[QBP]
(QBP − E[QBP ]), (2.9)
The authors conducted an evaluation of various tests including Box-Pierce and Ljung-Box.
The design of the adjusted Box-Pierce statistic (2.9) explicitly recenters and rescales QBP to
attain the mean and variance of a χ2(m) variable. The authors showed through simulations
that the test possesses very good adherence to nominal type I error rates. In their comparison
study, they found that both the distributions of QBP and QLB deviate from the expected
variance of χ2(m) distribution for small and moderate sample sizes and almost all choices
for the value of m.
All of the above-mentioned tests exhibit deviations from the nominal type I error rates that
compromise their performance. Thus, a new approach is proposed which aims at correcting
the rejection region instead of redesigning the test statistic itself. This technique was in-
troduced by Bernard in his effort to construct a more powerful alternative to Fisher’s exact
test [14] [15] and later by Boschloo [16]. The same idea of rejection region correction has
been recently employed by Ehwerhemuepha et al to produce the best performing test for
homogeneity for multinational distributions [17].
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2.1 Methods
A model based correction of the rejection region of the adjusted Box-Pierce test was designed.
A large scale simulation study was then conducted to not only estimate the correction, but
to also assess the performance advantages (defined as adherence to the nominal type I error
rates for all scenarios) of the proposed corrected method.
2.1.1 Simulation Study
For sample size values of n = 40, 50, . . . , 300, we simulated 106 white noise samples, sn1, sn2, . . . ,
sn106 ∼ Nn(0, I). These mimic the behavior of residuals of a well-fitting time series model
(under the null). Next, the adjusted Box-Pierce test was applied to every sample and for all
possible lags, m (2 ≤ m ≤ n − 1) and the corresponding p-values, pnm1, pnm2, . . . , pnm106
were obtained. For each pair (n,m), the estimated the type I error rate of the adjusted Box-
Pierce test at alpha level of 0.05 was empirically estimated by P
n,m
α=0.05 =
∑106
i=1 I{pnmi <
0.05}/106. Thus, for each sample size n, n − 2 empirically estimated type I error rates
yielding a dataset with three columns, n, m, and P
n,m
α=0.05. Further, these datasets obtained
from all individual sample sizes n were stacked to get an aggregated dataset with number of
rows
∑30
n=4 10n(10n− 2) = 934, 920.
2.1.2 Linear model
The primary idea of this study was to provide a model-based correction to the rejection
region of the adjusted Box-Pierce test in order to attain improved type I error rates for all
sample sizes and lags. We created six linear regression models trained on the simulated data
described in the section above. These six models were trained on different subsets of the data
split into sample size intervals, (0, 50],[51, 70], [71, 90], [91, 120], [121, 200], and [201, 300].
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The difference in the type I error rate patterns for distinct sample seizes (shown in Figure
1) necessitated the use of separate models to achieve the desired level of fit. These linear
models are complex as they encompass different powers of n, m and their 2-way interactions.
The general formula adopted for the models was,
Y − 0.05 = α1ns + α2mp + α3(ns ∗mp) + α4(n2s ∗m2p) + α5n2s
+ α6(n
3s ∗m2p) + α7(n3s ∗m3p) + α8m4p + α9m5p.
(2.10)
Further, within the general form (2.10) an extensive grid search to find the best values of the
power transformation parameters s and p was performed. The type I error rates from the
selected best models are presented in Table 4.2. The rates were calculated using validation
data with sample sizes of nval = 45, 65, 85, 100, 250.
Table 2.1: Performance summary of the correction to the
Adjusted Box-Pierce.
Sample size s p AdjBoxPierce Corrected version
n = 45 0.2 0.3 0.04868907 0.05001953
n = 65 10.0 1.0 0.05163921 0.05002905
n = 85 7.0 2.0 0.05305157 0.05045904
n = 100 1.3 1.7 0.05447408 0.05020469
n = 160 0.8 0.9 0.05629981 0.04987525
n = 250 1.9 0.8 0.05813593 0.05037286
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Table 2.2: Summary statistics for selected variables in
interval sample size less than 50.
Variable Estimate Std.Error t-value p-value
ns 0.425295 0.251604 1.690 0.095008 .
mp -1.353900 0.793110 -1.707 0.091837 .
ns ∗mp 0.593460 0.396921 1.495 0.138960
n2s ∗m2p 0.149028 0.056476 2.639 0.010065 *
n2s -0.183531 0.122355 -1.500 0.137706
n3s ∗m2p -0.070355 0.030893 -2.277 0.025539 *
n3s ∗m3p 0.004419 0.002064 2.141 0.035436 *
m4p -0.017762 0.004355 -4.079 0.000109 ***
m5p 0.002106 0.000461 4.570 1.83e-05 ***
Table 2.3: Summary statistics for selected variables in
finite sample size between 51 and 70.
Variable Estimate Std.Error t-value p-value
ns -2.652e-06 8.296e-07 -3.196 0.00179 **
mp 1.209e-03 2.984e-04 4.053 9.12e-05 ***
ns ∗mp -2.283e-07 7.347e-08 -3.108 0.00237 **
n2s ∗m2p -2.068e-12 3.852e-13 -5.369 4.07e-07 ***
n2s 4.910e-10 1.869e-10 2.627 0.00977 **
n3s ∗m2p 4.637e-16 8.877e-17 5.223 7.75e-07 ***
n3s ∗m3p -1.167e-18 2.439e-19 -4.784 5.05e-06 ***
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m4p 6.138e-10 2.856e-10 2.150 0.03364 *
m5p 2.552e-12 1.811e-12 1.409 0.16150
Table 2.4: Summary statistics for selected variables in
finite sample size between 71 and 90.
Variable Estimate Std.Error t-value p-value
ns 3.214e-17 2.901e-17 1.108 0.269585
mp 3.833e-06 1.130e-06 3.392 0.000877 ***
ns ∗mp -1.392e-20 3.309e-20 -0.421 0.674609
n2s ∗m2p -4.627e-36 6.406e-37 -7.224 2.02e-11 ***
n2s -6.756e-31 6.616e-31 -1.021 0.308740
n3s ∗m2p 9.423e-50 1.523e-50 6.189 5.00e-09 ***
n3s ∗m3p -1.759e-54 4.077e-55 -4.315 2.80e-05 ***
m4p 2.816e-17 2.774e-18 10.153 < 2e-16 ***
Table 2.5: Summary statistics for selected variables in
finite sample size between 91 and 120.
Variable Estimate Std.Error t-value p-value
ns 5.169e-06 3.434e-06 1.505 0.133211
mp 1.266e-05 3.809e-06 3.323 0.000994 ***
ns ∗mp -1.569e-09 9.362e-09 -0.168 0.867045
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n2s ∗m2p -2.021e-13 1.482e-14 -13.641 < 2e-16 ***
n2s -1.216e-08 7.488e-09 -1.624 0.105408
n3s ∗m2p 3.782e-16 3.539e-17 10.687 < 2e-16 ***
n3s ∗m3p -4.778e-20 4.874e-21 -9.804 <2e-16 ***
m4∗p 3.367e-15 1.792e-16 18.793 < 2e-16 ***
m5p -4.058e-19 3.561e-20 -11.397 < 2e-16 ***
Table 2.6: Summary statistics for selected variables in
finite sample size between 121 and 200.
Variable Estimate Std.Error t-value p-value
ns 5.966e-05 2.343e-05 2.546 0.01102 *
mp 8.195e-04 5.830e-05 14.056 < 2e-16 ***
ns ∗mp -1.227e-05 1.336e-06 -9.181 < 2e-16 ***
n2s ∗m2p -8.989e-09 3.701e-10 -24.290 < 2e-16 ***
n2s -1.271e-06 3.925e-07 -3.237 0.00124 **
n3s ∗m2p 1.864e-10 5.775e-12 32.280 < 2e-16 ***
n3s ∗m3p -1.079e-12 2.925e-14 -36.873 < 2e-16 ***
m4p 1.233e-09 8.712e-11 14.147 < 2e-16 ***
m5p 6.308e-12 6.042e-13 10.440 < 2e-16 ***
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Table 2.7: Summary statistics for selected variables in
finite sample size between 201 and 300.
Variable Estimate Std.Error t-value p-value
ns 1.740e-07 5.213e-08 3.338 0.000868 ***
mp 2.056e-04 5.313e-05 3.870 0.000114 ***
ns ∗mp 1.206e-08 5.327e-09 2.263 0.023777 *
n2s ∗m2p -9.680e-14 6.970e-15 -13.889 < 2e-16 ***
n2s -1.845e-11 2.884e-12 -6.396 2.22e-10 ***
n3s ∗m2p 5.841e-18 1.928e-19 30.295 < 2e-16 ***
n3s ∗m3p -5.966e-20 2.469e-21 -24.161 < 2e-16 ***
m4p -4.111e-09 5.612e-10 -7.326 4.14e-13 ***
m5p 1.660e-10 7.322e-12 22.678 < 2e-16 ***
2.2 Results
Noticeable differences between the patterns of type I error rates across the analyzed sample
sizes (40 to 300) were discovered. Therefore, sample-size specific models (0-50, 51-70, 71-90,
91-120, 120-200, 201-300) were constructed to capture the exact pattern for that particular
scenario. Table 4.2 displays a condensed form of the comparative study between revised ver-
sion of Box-Pierce, which to the best of our knowledge is the last version, and the correction
that we have brought into the study. For different time series lengths, the corresponding
s and p values along with the type I error rates for the adjusted Box-Pierce and those of
the corrected version that we designed. It is important to realize that the results from the
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implementation of these models show that in all settings, the proposed regression-based cor-
rection provided almost perfect type I error rates. In particular, the adjusted type I error
rates after the correction to the rejection regions were exactly 0.05 with detailed results.
Tables 2.2, 2.3, 2.4, 2.5, 2.6, and 2.7 show detailed summary from the sample-size specific
model fits. These models provide a parametric correction of the type I error rates. Graphical
representation of results from the implementation of these models for several scenarios are
shown in Figure 2.1.
Form left-to-right-up-to-down the fitting curves with appropriately found models in cases
where (n = 50, 70, 90, 120, 300) can be viewed. Empirically, it can be seen that the models
that best fit the specific curve in a given data were found.
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Figure 2.1: Parametric correction to the rejection region
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Figure 2.2: Parametric correction to the rejection region
2.3 Data example
An application of our corrected version of the adjusted Box-Pierce test was performed using
S&P 500 stock data. We provide instances of both false positive and false negative results
obtained by the standard adjusted Box-Pierce test using EQT Corporation stock. This cor-
poration created in 1884 and headquartered in Pittsburg is one of the leading companies
extensively devoted to the exploration and transportation of hydrocarbon (Petroleum, natu-
ral gas, natural gas liquid). The average daily price of the EQT Corporation was calculated
by collecting its opening and closing prices over a period over 8 years (2010-2018). For a
window size of 50, numerous false negative and false positive points were found at different
lags. In this case, instead of a critical value we have a critical boundary or curve exists. In
this setting, the same rejection conditions are the same as in the normal case.
In Figure 2.2, instances of a false positive rejection at lag 26 are shown where the adjusted
Box-Pierce test obtains a p-value of 0.0504 but the proposed model correction inflates the
rejection region to start at 0.058. The graph also shows a false negative results with p-value
of 0.046 at lag 47. However, the proposed correction shrinks the rejection region to start at
0.045.
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2.4 Discussion
In this work a new apparoch for correction of adjusted Box-Pierce test recently developed by
Kan and Wang [4]. Conceptually, the rejection region correction idea is similar to the ones
successfully employed in the work of [16] and [17] to counterbalance the conservativeness
of exact homogeneity tests. The provided method combines large scale simulations with
subsequent scenario-specific regression modeling that includes complex interaction terms to
achieve exceptionally good fit that entails nominal type I error rates for all sample sizes
and lags used in the test statistic. The regression models that were constructed depend on
the length of the series (n) and the lag order (m). The exponents (s) and (p) of different
variables present in the models are treated as hyperparameters in order to control the learning
process. To obtain optimal values for those hyperparameters an extensive search through
chosen subset values for (s) and (p) was conducted. The simulation study showed that the
test outperforms all existing competing goodness-of-fit approaches for sample sizes up to
300.
The merit to the novel correction to the adjusted Box-Pierce proposed in this study is that
it allows to find a test with vastly improved type I error rates. This proposed technique of
rejection region correction has direct implication on precise decision making by investors and
financial institutions. The same technique can be easily extended to larger sample sizes.
2.5 Summary
Building models forces us to translate our beliefs into the language of mathematics and/or
computer. More often than not, our believes are erroneous since they are based on as-
sumptions. In this process, we can either make under or over assumptions that could lead
to possible misleading us to wrong models with highly destructive consequences. To avoid
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eventual undesirable situations, it is always wise to check for the adequacy of our constructed
models.
To obtain a dream model, notable mathematical, computational and empirical techniques
have been proposed. Some rely on the graphical representation of the estimated residuals
and other focus on the plot of the residual autocorrelation and partial autocrrelation at
a certain number of lags. However, the first method could be subjective thus deceiving,
and the second method only looks at the magnitude and significance of the autocorrelation
coefficients at the individual but not jointly.
In trying to overcome the underscored weaknesses of the above mentioned diagnostic of
Goodness fit tests, more robust techniques such as Box-Pierce, and Ljung-Box have also
been proposed. Despite their success and mathematical soundness, the classical Box-Pierce
and Ljung-Box tests for auto-correlation of residuals also present serious flaws, such as severe
deviations from nominal type I error rates. As a response, many efforts have been deployed
to address this issue by either revising existing tests or designing new techniques. Among all
the refined versions of Ljung-Box tests, the Adjusted Box-Pierce demonstrated a superiority
by achieving the best results with respect to attaining type I error rates closer to nominal
values. Nevertheless, the Adjusted Box-Pierce seems to reject too much.
In this work, we proposed a further correction to the adjusted Box-Pierce test that possesses
near perfect type I error rates. The approach is based on an inflation of the rejection
region for all sample sizes and lags calculated via a linear model applied to simulated data
that encompasses a large range of data scenarios. Our results show that the new approach
possesses the best type I error rates of all goodness-of-fit time series statistics.
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3 New Risk Factors for Emergency
Department Return Visits within 72
Hours for Children with Respiratory
Conditions
3.1 Introduction
Chronic respiratory diseases constitute a set of conditions that mainly affect the airways
and other parts of the lung. Chronic respiratory diseases have become a complex world-
wide epidemiological phenomenon that is highly associated with increased morbidity and
mortality[18], [19], [20]. Comparative information about the disease prevalence, visits and
returns to emergency departments, financial and death rates show that chronic respiratory
diseases have become one of the biggest public health and economic burdens claiming 2.5
million lives and costing $8.1 billion in health care costs in 2019 [21], [22], [23], [24], [25].
Globally, more than one billion people suffer from chronic respiratory diseases and an es-
timated 4 million die each year [26]. Chronic respiratory infections are reported to be the
leading cause of mortality and morbidity in low- or middle-income countries (LMICs) [21],
[22], [23], [24], [25] and [26]. As a result, respiratory infections have become an increasingly
important part of the global public health efforts and research.
Asthma is another dangerous and prevalent condition with global burden of disability [27],
[28], [29]. The Global Asthma Network (GAN), which aims to reduce the suffering from
asthma by preventing asthma case with focus on low- and middle-income countries (LMICs),
reported that almost 339 million people are affected with Asthma [30]. Annually, asthma
is responsible for the death of 489,000 people [21]. With its high rate of mortality and
morbidity, asthma is ranked among the top 20 causes of years of life lived with disability. In
addition to the death tolls, asthma treatment has high economic burden [31].
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Acute lower respiratory infections (ALRIs) kill approximately four million people every year,
with higher impact on low and middle income countries [32] placing them among the top
three causes of death around the world [30]. For example, in 2015, approximately 2.38 million
people lost their lives because of ALRIs [33]. Recently, considerable amount of efforts has
been deployed to reduce the death tolls of ALRIs, nevertheless their importance remains
underestimated mostly in some regions of the globe [33].
Tuberculosis (TB) has long been viewed as one of the most dreadful preventable infectious
diseases. Tuberculosis infects approximately 2 billion people of whom an estimated 2 million
of people die yearly [34]. According to WHO, the costs of TB treatment and management
represent a disproportionately high burden to patients, their families and communities and
governments. For example, each year, tuberculosis accounted for approximately $21 bil-
lion including $9.2 billion for treatment and control activities and $12 billion in additional
economic costs and lost productivity.
Lung cancer is one of the cancers with the highest mortality rate which claims more lives
than any other type of cancers [35]. In 2012, there were 1.8 million new cases and 1.6 million
deaths. In 2015, 1.7 million lives were lost due to lung cancer, representing almost 20% of
all cancer-related deaths in the world [36].
Sadly, a great number of patients with chronic respiratory conditions are newborn babies
and small children. Recent research efforts have reported that chronic respiratory diseases
are the conditions related with the highest death rate among children under five years of age.
Chronic Obstructive Pulmonary Disease (COPD), though being conventionally accepted to
be associated with smoking among quadragenarians or older patients[37] also affects many
children. In some studies, it is reported that COPD could take its roots in childhood by
living with adult smokers in the same household [38]. Further, it has been reported that
there is a strong association between childhood death from COPD and poverty [39].
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Asthma is the most common, but non-communicable chronic disease that not only impacts
the quality of life of children, but also significantly contributes to childhood mortality and
morbidity worldwide [40], [41] with a death rate ranging between 0.0 to 7.0 per 1,000 [24].
On a global scale, 14% of children are affected with asthma and as high as one-third of US
children population [42].
Presently, there is no known cure for asthma. However, the disease can be managed with
adequate prevention and treatment therapy. According to recent Center for Disease Control
(CDC) data, 1 in 13 people have asthma resulting in ∼25 million Americans having the
disease and sadly, children account for ∼8% of the patients. Asthma has been on a steady
increase in the last three decades affecting all ages, gender, and ethnicity. Asthma is the
leading chronic disease in children, and it is more common in boys than in girls. Strikingly, it
is the top reason for school absenteeism among school children. In 2013, ∼13 million missed
school days were attributed to asthma. In 2015 and 2016 CDC data, it was observed that
48% of children ages 18 and under who had the disease reported having at least one asthma
attack in the previous year. Likewise, ∼50% of children under the age of 5 with asthma had
an episode.
The financial implications of asthma are enormous with an annual economic cost in the
worth of $80 billion between 2008 and 2013 [31]. The annual per-person incremental medical
cost of asthma was approximately ∼$3,200 in 2015 [31].
Globally, the prevalence of asthma in children has been on the rise [43], [44]. Burr et
al., between two different studies, outlined an increase of 6.5% in the prevalence [45]. A
similar trend in the prevalence of asthma was reported by Burney and Aberdeen in [46],
[47]. With an increasing prevalence, asthma has progressively become the most frequent
cause of hospitalization among children [48]. In theory, the prevalence of asthma symptoms
is assumed to attain higher levels in developed or high-income countries (HICs), however
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LMICs have recently displayed alarming prevalence rates. Recent studies showed that more
severe childhood asthma cases are seen in LCMIs with over 80% of asthma-related deaths
occur in LMICs [49], [50].
Tuberculosis (TB) is another respiratory infection causing a pronounced increase in morbidity
and mortality in children around the world [51], [52], [53] particularly among those from
geographic locations with high incidence and prevalence of HIV [49], [54]. Due to poor
recording and reporting of childhood TB cases, lack of resources, and limited amount of
pediatric surveillance data, quantifying and estimating accurately the global pediatric burden
of TB has been subject of great debates [55], [56], [57]. Nevertheless, a staggering number
of pediatric pulmonary tuberculosis cases have been encountered. For example, in 1989
the World Health Organization (WHO) claimed that 450,000 deaths in children under 15
years of age occur almost every year [58]. In 2000, an estimated 8.3 million new cases of
tuberculosis and 1.8 million of deaths were reported [56], [59]. In 2014, WHO indicated
that approximately one million new cases occurred among children, of whom 136,000 died
[60]. Though considerable efforts have been recently deployed to control the prevalence and
incidence of TB cases, tuberculosis remains a serious public health challenge.
The exacerbation of chronic pediatric respiratory conditions is generally associated with
unscheduled returns to the emergency department (ED) within 72 hours. By return visits
to the ED, we refer to the definition given by De Sales et al. as the return of a patient to
the ED because of the initial complaint within 72 hours from being discharged [61]. Though
unplanned return visits to the ED are generally related to the progression of the illness [62],
[63], many other factors and scenarios including the quality of the health systems that take
patients in, medical errors, persistence of the parents for extra-care may also be involved
[64], [65]. Another important concern is that ED 72-hour revisits impose burdens not only
on patients and their families, but also to insurance providers. Unscheduled readmissions
may lead to overcrowding of medical facilities and incur financial burdens on hospitals [66],
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[67]. Return to ED rates have been used as a metric to assess the quality care provided
to patients, where higher rates are widely used to designate inappropriate treatments or
eventual medical errors [62]. Today, the rate of return visits to the ED is the metric of
choice for measuring care quality in the ED. In recent literature, a generally accepted rate of
return visit to the ED is estimated to be less than 1% [61]. According to other researchers,
return visit rate ranges between 2.5% and 5.2% for emergency departments [66], [63], [68].
In contrast, [69] indicated that site-specific 72-hour return visit rates ranged from 1.1% to
15.2%. A great number of the previous studies related to the association between chronic
respiratory conditions and the rate of ED return reported some factors such as young age,
health insurance coverage, higher acuity to be the main causes for returning visits to the
ED [70], [66]. Other studies have reported that the greater rate of returning to the ED is
significantly associated to young age [66], [63].
Little research has been conducted to investigate new risk factors for return ED visits for
patients with existing respiratory conditions. Nevertheless, [71] reported that antimicro-
bial prescription for upper respiratory infections among patients covered by Medicaid has
decreased, and that there is no association between the prescription and the decrease in
subsequent return visits. [63] studied the frequency of pediatric 72-hour return visits to
the ED between 2001 and 2007. A significant increase in the return visit rate was noticed
between 2001 and 2007. The authors also found factors such as age, arrival time to the ED,
recent discharge from the hospital, and some geographical regions of the US to be strongly
associated with return visits to the ED.
In this study, we provided comprehensive analyses of return visits in the pediatric ED settings
among children with chronic respiratory conditions. We identified all statistically significant
respiratory conditions that are predictive for return ED visits among children that have been
discharged within 72 hours. We estimated the magnitude and directions of the effects sizes,
allowing hospitals, healthcare facilities and public health institutions to design and adopt
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a more accurate and advantageous regulation for handling high risk patients. Lastly, we
implemented several machine learning algorithms to find the best predictive model for ED
readmission within 72 hours for children with existing pulmonary conditions.
3.2 Methods
We conducted this multicentered epidemiological study using data queried from the large
Health Facts database. This database is a repository of de-identified medical data from 650
hospitals centers throughout the United States containing complete details of all patient
visits since 2015. The existing data in the database are obtained from electronic medi-
cal records, which are also provided by contributing hospitals and organizations. These
records can include encounter data (emergency, outpatient, and inpatient), provider spe-
cialty, demographics (age, sex, and race), diagnoses and in-hospital procedures documented
by ICD-9-CM codes, laboratory data, pharmacy data, in-hospital mortality, and hospital
characteristics [72]. While a range of hospitals and other medically related entities from
different horizons around the country collect the data, Cerner Corporation is the principal
representation that mainly captures, centralizes, and stores the data. As of 2018, Health
Facts brings together information from 90 health centers and 650 facilities across the states.
In this study, we however decided to use the International Classification of Diseases, Tenth
Revision, Clinical Modification (ICD-10-CM) to determine patients treated from respiratory
conditions not associated with cancer and as captured by ICD-10-CM codes J00-J99.
We conducted a retrospective case-control study of patients under 18 years of age nested
in the larger cohort of all patients. The selected patients were admitted in 166 emergency
departments. The approval to conduct this was given by the CHOC Children’s Hospital
Institutional Review Board (IRB 180857). The used deidentified dataset contains the ad-
mission data of approximately 1.7 million patients that were admitted in pediatric emergency
23
departments (EDs). The available demographic variables were race (Caucasian, Hispanic,
African American, and Black, Asian Pacific Islander, Native American, unknown), age and
sex. The demographic variable age was divided into three categories: (0, 5], (5,12], and
(12,18]. Patients whose sex information was not available were excluded from the study.
The type of insurance was used to approximate the individual patient’s socioeconomic sta-
tus. The patients involved in this study use one of the insurance types (commercial, Medicare
Medicaid, 2 other government insurance types, self-pay, and others). Since chronic respi-
ratory conditions can result in unplanned return to the ED and higher hospital utilization,
related variables were added. The key reason for this is that hospital utilization generally
relates to the efficiency of the care-quality received by patients. As such, the hospital utiliza-
tion variables used as explanatory variables are Previous ED visit, Ispediatric, Has History
of Return Visit and number of medicines taken by the patient, and length of stay (LOS).
The patient’s length of stay was also divided into four categories: (0, 4], (4,8], (8,16], (16,24].
Some of the most common respiratory conditions coded as Acute Nasopharyngitis[common
cold] (J00), Acute Sinusitis(J01), Acute Pharyngitis (J02), Acute Tonsillitis (J03), Acute
Laryngitis (J04), Acute Obstructive Laryngitis and Epiglottitis (J05), Acute Upper Res-
piratory Infections of Multiple and Unspecified Sites (J06), Influenza due to certainidenti-
fied influentza viruses (J09-J11), Viral Pneumonia, not elsewhere classified (J12), Bacteria
and Other Pneumonia (J13-J18), Acute Bronchitis(J20), Acute bronchiolitis (J21), Vasomo-
tor and Allergic Rhinitis (J30), Chronic Rhinitis, Nasopharyngitis and Pharyngitis (J31),
Chronic Sinusitis (J32), Chronic disease of tonsils amd adenoids (J35), Nasal Polyp Other
Unspecified Disorders Nose Nasal Sinuses (J33-J34), Peritonsillar Abscess (J36), Other dis-
eases of Upper Respiratory tract (J39), Bronchitis, not specified as acute or chronic (J40),
Simple and Mucopurulent chronic bronchitis (J41), Unspecified Chronic Bronchitis (J42),
Emphysema (J43), Asthma (J45), Acute Respiratory Distress Syndrome (J80), Suppura-
tive and Nectrotic of Lower Respiratory Tract (J85-J86), Pleural effusion, plague, and other
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pleural conditions (J90-J92, J94), Intraoperative and Postpreocdural complications and Dis-
orders not classified elsewhere (J95), and Other diseases of the respiratory system (J98-J99
) were included in the study. Table 3.2 displays the prevalence rate of the concerned respira-
tory conditions. addition, Surgical procedures during the index ED visit were not included
in the study, but they were also classified into auditory, cardiovascular, digestive, integumen-
tary, musculoskeletal, and urinary/reproductive system surgery using the current procedural
terminology code version 4 (CPT-4). Furthermore, we estimated the 90th percentile of
the number of medications administered during the ED visits and categorized patients into
2 groups: patients who received greater than the 90th percentile and those that did not.
Lastly, we excluded data from all ED facilities that have had less than 100 return visits as
they corresponded to facilities with disproportionately small number of encounters and may
be a result of data entry error and noise.
As seasonal variation is known to be also responsible for clinical discomfort to patients
with chronic conditions and an increase of the hospitalization rate and that of return to
ED, we decided to categorize the variable that describes the month at which the patients
were readmitted in ED into 4 categories. Winter (December 1st- February 28th or 29th in
leap year) was mapped to 0, Spring season (March 1st – May 31st) to 1, summer (June
1st – August 31st) to 2, and Autumn (September 1st – November 30th) to 3. Patients
were excluded if they have respiratory condition occurrence rate less than 1,000 and several
medications (> 10). The primary reason for this is to make sure that we include only
facilities that have seen large number of patients with respiratory conditions. The secondary
reason for this selection technique is also exclude noise in the data in relation to ED facilities.
Subjects who also spent more than 24 hours in ED were also dropped in the study.
In the study, the multicollinearity in the data was assessed by estimating the generalized
variance inflation factor (GVIF) of each of the variables. GVIF is a statistical tool that
quantifies the degree of correlation between the predictors present in a given model. One
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mission of GVIF is to identify variables that are highly correlated with each other. Another
mission of GVIF is to be able to assess the contribution of involved variables in the model.
Addressing the degree to which variables are correlated (multicollinearity) improves the mea-
surement of association between a variable within a model and the outcome it is predicting.
This decision was made, a priori, to exclude all variables with GVIF greater than 4 – a rule
of thumb threshold based on previous studies [73], [74], [75].
The data used in this multicentered epidemiologic study were prepossessed HealthDataLab
using Center Corporation – an elastic parallel distributed high-performance cloud computing
platform running on Apache Spark Since our data are clustered by Hospital ID and Patient
ID, a mixed random effects logistic regression model was deployed to conduct a multivariate
analysis. Thus, a random intercept model was built to model the return to the ED within 72
hours, a binary outcome variable. The model building and statistical analysis were preformed
using R statistical Software. The machine learning models were constructed using Python
Computing Programming Language
We implemented 15 high-accuracy machine learning classiication models such as Decision
Tree (DT), K-Nearest Neighbors (KNN), Gaussian Näıve Bayesian (GNB), Multinomial
Näıve Bayesian (MNB), Complement Näıve Bayesian (CNB), Multinomial Logistic Regres-
sion (MLR), Multi-Layer Perceptron (MLP), Ridge Regression Classifier (RRC), Linear
Classifiers with Stochastic Gradient Descent (LCSGD), Passive Aggressive Classifier (PAC),
Linear SVC (SVC), Random Forest (RF), Extremely Randomized Trees (ERT), Gradient
Boosting Tree (GBT), and Extreme Gradient Boosting Tree (EGBT) on the task of clas-
sifying subjects as patients that have been readmitted, or not readmitted 72 hours after
discharge. Using grid-search, hyper-parameter tuning optimization across different models
was carried out. The optimal values of the hyperparameters were selected based on the AUC
over 10-fold validation datasets. The implementation of the adopted machine learning al-
gorithms and the hyper-parameter tuning were done in python and while using scikit-learn.
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Table 3.1 displays the names of the machine learning algorithms involved in this study, the
names of the considered hyperparameters and the values and options they assume. The
choice of these machine learning algorithms, associated hyperparameters and their values
was inspired by a study recently done by Zhen and colleagues (Zheng et al., 2020).
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Table 3.1: Hyperparameters Table
Model Name Hyperparameter Name Hyperparameter Options
DT criterion ’gini’,’entropy’
splitter ’best’,’random’
max features ’auto’,’sqrt’,’log2’,None
KNN n neighbors 15 31
weights ’uniform’,’distance’
algorithm ’ball tree’,’kd tree’
GNB var smoothing 10−7∼−12
MNB alpha 0, 0.1, 0.5, 0.8,1
CNB alpha 0, 0.1, 0.5, 0.8,1
MLR solver ’newton-cg’,’lbfgs’,’saga’,’sag’
RRC alpha 1e-3, 1e-2, 1e-1, 1
solver ’svd’, ’cholesky’, ’lsqr’, ’sparse cg’, ’sag’, ’saga’
LCSGD loss ’hinge’,’log’,’modified huber’,’squared hinge’,’perceptron’
alpha 1e-3, 1e-2, 1e-1, 1
learning rate ’constant’,’optimal’,’invscaling’,’adaptive’
eta0 0.01, 0.001, 0.0001
PAC C 0.001, 0.01, 0.1,1
loss ’hinge’,’squared hinge’
SVC loss ’hinge’,’squared hinge’
C 0.001, 0.01, 0.1, 1
RF n estimators 300, 500, 800
criterion ’gini’, ’entropy’
bootstrap True, False
max features ’auto’, ’sqrt’, ’log2’,None
ERT n estimators 300,500,800
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criterion ’gini’, ’entropy’
bootstrap True, False
max features ’auto’, ’sqrt’, ’log2’,None
GBT loss deviance, exponential
learning rate 0.1 , 0.01, 0.001, 0.1
subsample 0.1, 0.5, 0.9
n estimators 300, 500, 800
max features ’auto’, ’sqrt’, ’log2’, None
EGBT tree method ’auto’, ’exact’, ’approx’, ’hist’
grow policy ’depthwise’, ’lossguide’
n estimators 300, 500, 800
learning rate 0.001, 0.01
max depth 10, 15, 20, 50, 100
MLP hidden layer size (50,50,50), (50,100,50), (100,)
activation ’tanh’, ’relu’
solver ’sgd’, ’adam’
alpha 0.0001, 0.05
learning rate ’constant’, ’adaptive’
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Figure 3.1: ED return proportions with respect to patient’s age
3.3 Results
To make inference about the whole enrolled patients and identify statistical and causal
associations between variables that are present in the data at the time of the study and the
ED return within 72-hours after discharge to home, univariate and multivariate analyses are
then performed. As such, refers to Table 3.2, and Table 3.3 for results generated from the
univariate study, and to Table 3.4, and Table 3.5 for outputs obtained from the multivariate
counterpart.
Patients and ED return Rates
In this study, the total sample size was 1,513,333, where the subjects were distributed among
166 hospitals across the nation. A total number of 48,828 (3.23%) returned to ED within
72 hours versus 1,464,505 (96.77%) who did not return to ED at least in the next 72 hours.
Thus, ED readmission is a relative event that induces imbalanced data. Per our modeling
objective, we partitioned the obtained dataset into training and validation sets in 75-25%
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Figure 3.2: Return proportions with respect to the time spent by patients in ED
ratio respectively. The train set was used for learning purposes, while the remainder of the
data was used to validate the models. Exploratory analysis and descriptive statistics of the
demographic and clinical characteristics of the involved subjects present in the training set
are displayed in Table 3.2, and Table 3.3. Among all the eligible patients in the training
set, 46.51% were female while 53.49% were male. Of these patients 42.36% were Caucasian,
31.22% were African American, 7% were Hispanic, 1.24% were Asian Pacific Islander, 2.34%
were Native American and 16% were of non-identified ethnic or racial group(s). Approx-
imately, 57.60% of the eligible subjects were on Medicare or Medicaid versus 23.32% on
Commercial Health Insurance, and 10.77% in other types of insurance. Only 6.03% of the
children were either covered by their family and 2.26% of the patients were under other
governmental insurance. The majority (57.67%) of the patients were 5 years of age or less,
against 29% aged between 5 to 12 and 14% of the encounters older than 12 years of age.
Above all these, the information in the training set indicates that the rate of return to the
emergency department within 72 hours after being discharged was only of 0.032.
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Demographic and Socio-economic Characteristics vs ED Returns
From our statistical analysis, we observed that the readmission rates in male patients is
higher than in female patients as shown in Table 3.2. Strikingly, we found the existence
of a significant (P< 0.001) association between other demographic characteristics such as
participant’s age, length of stay, race/ethnicity, and their medical insurance and ED return
rates. Participants less than 5 years old were the largest number of participants to return
in ED. Figure 3.1, for example, displays the proportion ED returns visit with respect to
patient’s age. Such a proportion follows a quasi-parabolic shape where the maximum number
of unscheduled returns to ED is more pronounced with children that are less than 5 years.
The absolute minimum of such a proportion is achieved among children that are 5 to 10 years.
Though readmission rate to the ED was higher among children older than 5 and less than 12
years of age, it was not as common as with children of less than 5 years of age. The remaining
demographic/Payer/Resourceutilization variables have significant association with pediatric
patients revisiting the ED. It can then be concluded that demographic variables, proxies for
socio-economics status and those for hospital resources are eminent risks factors to the ED
Returns(Figure 3.2).
From our multivariate analysis, we observed that the time spent by patients in the ED during
the last six (6) months is associated with higher odds of returns to the ED. Interestingly, we
discovered that the longer the length of stay, the higher the odds of returns to the emergency
department became. Patients that spent 16 to 24 hours in the ED have 30.4% increase in
odds of return, followed by the ones that spent 8 to 16, and 4 to 8, with 15 and 13% odds of
return. Next to the length of stay, proxies of socio-economic statuses come in term of being
associated with the risk of return to ED. The model reveals that besides patients, regardless
of the type of insurance they own, have an increase in the odds of an unscheduled readmission
to the ED returns. Patients that have insurance of type “others” have the highest increase in
odds (20%), followed by those who have other governmental insurance, Medicare or Medicaid
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with, approximately, 14-, 13-, 4% respectively of likelihood to unexpectedly return to the
ED. Also, we observed that patients that were of ages 5 to 12 had higher drop (22%) in the
odds of a return visit than patients that are older than 12 years of age who present have a
19% drop in odds of a return visit. Furthermore, we examined the importance of race and
ethnicity in the ED. Strikingly, we found that patients of with African American descent
had a 6% decrease in the odds of a return visit. The remaining ethnic group did not display
any statistical significance. Patient’s past hospitalization, previous ED visits and history
of return visits are highly associated with the risk of a return visit. In addition, they all
have an increase in the odds of return visit ranging from 16% to 124%. The free-standing
pediatric ED variable appears to not be statistically significant.
We also found that the number of medications administrated the patients is statistically
and significantly associated with the odds of a return visit in the ED within 72 hours. In
multivariate analysis, we found that patients that are taking more than 3 medications have
almost 40% increase in the odds.
Seasonal effects vs ED Returns
From our examination of seasonal effects and ED returns, we realized that seasonal effects
significantly impact the rates of returning to the ED (Table 3.2). For example, the ED return
visit rate varied by periods of the year. The ED return visit rate is higher in Winter (32%)
followed by ∼19, ∼50 and ∼19% decrease in Spring, Summer and Fall semesters respectively.
However, there is a decrease in the ED return visit rate (∼38%) from Spring to Summer
against an increase of almost 63% between Summer and Fall. Overall, seasonal effects should
be taken as a major cause for patients under 18 to return to the ED. In the multivariate
analysis, we can see a reduction in odds in Spring and Fall (1.2 and 7.2%, respectively)
versus an increase in odds of ED return visit in Summer. Noteworthily, we found that Fall
semester significant risk factor that contributes to the ED return visits.
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Diagnoses vs ED Returns
In the diagnosis and ED return examination, we found that the rate of return to the ED
is significantly (P < 0.001) affected by some types of diagnoses (Table 3.2). For exam-
ple, besides Mental and Behavioral disorders (F01-F99), Diseases of the nervous system
(G00-G99), Diseases of the musculoskeletal system connective tissue (M00-M99), Preg-
nancy/Childbirth/Puerperium (O00-O9A), some conditions related to the perinatal period(P00-
P96) and Congenital and Chromosomal abnormalities(Q00-Q99), the remaining diagnoses
constitute statistically significant (P < 0.001) risk factors to the ED return visits. The rate of
return visits was higher with patients diagnosed with Diseases of the eye and Adnexa (H00-
H59), infectious/Parasitic diseases (A00-B99) and diseases of the digestive system(K00-K95),
13, 9, and 8%. In multivariate analysis, we found that apart from Congenital chromosomal
abnormalities (Q00-Q99), Injury/Poisoning/Consequences of External Causes (S00-T88),
and Diseases of the eye and Adnexa (H00-H59) and that have 12, 19 and 20% decrease in
odds of return visits, the remaining diagnoses have an increase in odds( between 6 and 71% )
of return visits. Of these diagnoses known as risk factors for patients to return to emergency
department, only infectious/Parasitic diseases (A00-B99), Diseases of the blood and blood-
forming organs and certain disorders involving the immune mechanism (D50-D89), Diseases
of the eye and adnexa (H00-H59), Diseases of the digestive system (K00-K95), and Diseases
of the genitourinary system (N00-N99) are statistically significant.
Respiratory Conditions vs ED Returns
In our respiratory conditions and ED returns analysis, we observed that the relationship be-
tween respiratory conditions and rate of ED returns is also outlined (Table 3.3). Respiratory
conditions associated with significant ED returns are : Acute sinusitis (J01), Acute pharyngi-
tis (J02), Acute tonsillitis (J03), Acute obstructive laryngitis and epiglottitis (J05), Acute up-
per respiratory infections of multiple sites (J06), Influenza (J09-J11), Viral pneumonia (J12),
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Bacteria and other pneumonia (J13-J18), Acute Bronchitis (J20), Acute Bronchiolitis (J21),
Vasomotor and allergic rhinitis (J30), Chronic rhinitis/nasopharyngitis/pharyngitis, Chronic
sinusitis (J32), Nasal polyp/other nose or nasal infections (J33-34), Peritonsillar abscess
(J36), Other chronic lower respiratory diseases (J40-J43) and Intraoperative/postprocedural
complications/disorders of the respiratory system (J95). Patients diagnosed with Acute up-
per respiratory infections of multiple sites (J06) and Acute pharyngitis(J02) had the highest
proportion of returns (37% and 18%, respectively). Alongside these conditions are aligned
Acute bronchiolitis (9%), Nasal poly/other nose or nasal infections (8%), and Bacteria and
other pneumonia (7%) as conditions with high ED revisit rates. In multivariate analy-
ses, patients who suffered from Peritonsillar Abscess (J36), Viral pneumonia, not elsewhere
classified(J12), Acute bronchiolitis (J21), Bacteria and other pneumonia (J13-J18) and res-
piratory conditions (J90-J92, J94) have higher increase odds (127%, 44%, 39%, 27.3% and
16% respectively) of a return visit.
Patients diagnosed with Acute pharyngitis, Asthma (J45, though not being statistically
significant in univariate case), Acute upper respiratory infections of multiple sites, Acute
nasopharyngitis/common cold have reduced 5, 8, 9, and 10% decrease in the odds of a return
visit. It was also found that certain respiratory conditions such as Acute tonsillitis (J03), resp
(J4044COPD1), Chronic sinusitis (J32) and Acute bronchitis are associated with reduced
odds (10, 11, 14 and 18%, respectively) of a return visit. Conditions like Acute sinusitis (J01),
diseases of upper respiratory (J39), and Chronic diseases of tonsils and adenoids (J35) have
also reduced odds (23, 26, and 28%) of a return visit.
Comorbidities Surgical Procedures vs Returns
As of the association of the simultaneous presence of other chronic diseases or conditions and
the rate of returns, Table 3.2 indicates that the most common causes for unscheduled returns
to ED are Cardiovascular surgery (CPTA:69000-69979), and Urinary/Reproductive system
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surgery (CPT4:50010-58999). They constitute serious risk factors of returning to emergency
department within 72 hours, with rates of returns 48 and 23%, respectively. Though the read-
mission rates among patients that went through Integumentary surgery (CPT4:10030-19499),
Musculoskeletal surgery (CPT4:20100-29999), Auditory surgery (CPT4:69000 -69979), and
Digestive surgery (CPT4:40490-49999) have higher ED rates of returns (15, 14, 13, and 12%
respectively), they remain variables that are not statically significant. In the multivariate
analysis setting, besides Digestive surgery (CPT4:40490-49999), which is not statistically sig-
nificant, the remaining surgical procedures were associated with very high risk of return visit.
With Patients that underwent cardiovascular, Integumentary and Urinary/Reproductive sys-
tem surgery (CPT4:50010-58999), there is at least 49% and at most 80% increase in odds of
return visits.
Table 3.6 exhibits the average AUC of the 10-fold cross validation testing for the 15 machine
learning models chosen in this study. The best performance was achieved by the Extreme
Gradient Boosting model over all the considered tested models with AUC of 0.645. Another
observation is the poor over all performances of the considered machine learning models. This
can be presumably due the inability of machine learning models to effectively predict return
visits given the current data under investigation. Another reason for these comparatively
poor performances could be that return visits may be influenced by factors that are not
clinical in nature but driven by behavioral patterns of the families with these patients.
3.4 Discussion
Unexpected returns to ED within 72 hours after being discharged generate consequential
economic and social damages. Therefore, identifying the associated preeminent risk factors
that could lead to such undesirable situations has been increasingly growing to be a focal
point for parents, medical staff and hospital management as it can, at least, lead to better
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further decisions.
The present study found that despite that male patients have a higher chance of revisiting
ED than female patients; gender is not associated with higher risk for ED return within 72
hours after being discharged. This is consistent with what was found by [19], [76], [77]. Our
model indicates that patient’s age is proportional to the drop rate in the odds of a return
visit to ED. This tells us that younger patients are more likely to revisit the emergency
department. A similar result was reported by [62]. Such a finding is presumably due to
the fact that when children are younger, they are expected to have have a weaker immune
system.
Interestingly, our model indicates that the duration of a single episode of hospitalization
is most likely to be a significant risk factor for ED readmission. Patients that have spent
a longer time have a higher chance of revisiting ED within 72 hours after discharge. This
result could be related to the fact that the time spent in the medical facility could be a good
indicator of unwell the patients could be. Regarding race, African American patients are
more likely to return to the ED within 72 hours more than Caucasian patients. In terms
of insurance type, patients on Medicare/Medicaid or Other governmental insurance or other
types of coverage are more likely to returns to the ED. Our model also indicates that previous
ED visits were a very strong predictor of at-risk patients. In fact, the number of previous
ED visits was found to be proportional to the risk of returning to the ED. Precisely, patients
that have previously visited ED the most are at higher risk of making another return.
In terms of chronic respiratory conditions, we found that patients suffering from complica-
tions coded with J01, J06, J09-J11, J13-J18, J20, J21, J31, J36, and J45 are more inclined to
return the the ED within 72 hours after being discharged. Identifying patients that display
these medical complications is of great importance as it can help clinicians to : (1) know
which patients need extra care or special attention, (2) make better orientation decisions,
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(3) determine which patients will need post-ED support, (4) determine what type of support
should be provided to the concerned patients, and (5) educate the patients risks that could
exacerbate their conditions. Nevertheless, it shall be noted that most of the respiratory
diagnoses are unlikely to result in an ED revisit.
In this study, we surprisingly found that the presence of some comorbidities was strongly asso-
ciated higher chance to unexpectedly return to ED with 72 hours after discharge. We noticed
found that patients that are suffering from Intraoperative and postprocedural complications
and disordered (J95), Cardiocascular surgery (CPT4:33010-19499), Integumentary surgery
(CPT4:10030-19499), Unirary/Reproductive system surgery(CPT4:50010-58999) were in-
clined to revisit the emergency department unexpectedly.
Arguably, building models, regardless of their nature, involves caveats and limitations that
are generally related to lack of extra information (i.e data), under or over assumption. Simi-
larly, this study suffers from a variety of weaknesses. Firstly, the data used for this investiga-
tion is administrative data. This insinuates the presence of eventual coding errors during the
period of assigning diagnosis codes to patients. Secondly, our data set is highly unbalanced
in favor of not returning to the ED within 72 hours after being discharged. Thirdly, it should
be known that despite the broad geographical distribution of the enrolled EDs across the
country, it will be risky to consider the involved population in this study could be taken as
a viable sample representative of all the children undergoing chronic respiratory conditions.
Therefore, the study findings should not be generalized to all the children suffering from
respiratory conditions. Fourthly, the data set that we use for modeling purposes does not
tell us exactly how the patients were enrolled in this study. Plus, we do not have any infor-
mation about patients’ care during their previous visits. Knowing this may be help orient
the efforts during their next appearance in the emergency department. Fifthly, the cohort
of patients in this study was based on patients discharged home from the ED. This implies
that we missed patients admitted to the hospital through the ED and return to the ED after
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discharge from the hospital. Such a limitation is, however, one of design and related to the
question being asked. In our case, we are concerned in elucidating the difference between
patients who return to the ED and those who do not among patients discharged home from
the ED (and deemed not requiring hospitalization).
Besides the information about the type of insurance used by the patients, no other socioe-
conomic status is available. For example, the level of education could be used to investigate
the degree of awareness of parents with respect to the utilization of ED resources.
Also, this study suffers from the way the study was designed. For example, our mixed
random effect model enables determine which variables could be seen as major risk factors
of return to the emergency department. However, it does not inform us about which ED
return was avoidable. Another limitation that could come from the study design is that
some of the return visits that were captured may have been unavoidable which we were not
able to capture/establish in this study.
Despite the above highlighted caveats and limitations, the contributions and implications of
this study are noteworthy. This study may help to (1) inform the patients about causes and
risk factors that could lead to a potential exacerbation of their health conditions; (2) educate
parents on the urgency of pediatric conditions; (3) provide EDs with what is necessary to
determine which interventions might be needed; (4) measure the effectiveness of the services
provided by EDs; (3) proffer ways to improve the quality of care of patients at risk; and (4)
construct very solid future strategies that could help drastically reduce potential avoidable
ED return visits.
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3.5 Conclusion
This multicenter study of pediatric return visits within 72 hours among patients with res-
piratory conditions across 166 emergency departments established that revisits within such
short period of time may be driven more by non-respiratory comorbidities than the under-
lying respiratory conditions. This pattern may differ as the window is increased to a value
greater than 72 hours. However, peritonsillar abscess, pneumonia, and bronchiolitis exposes
pediatric patients to higher odds of return visit. These findings indicate that ED providers
should pay closer attention to the respiratory risk factors as well as the comorbid conditions
that patients with respiratory conditions may present with. Corresponding improvements in
the quality of care and in the education of patients and their families may result in reductions
in return visits to the ED.
3.6 Summary
Understanding and dealing effectively with complex processes, such as emergency department
(ED) return visits, in order to better predict and efficiently minimize associated risks have
been the subject of virulent debates and the ground of countless arguments. In the past few
decades, academics, health management experts and insurance companies have proposed a
forest of techniques for reaching a better destination with respect to with ED return visits.
Among other approaches, predicting patients that are more likelihood to have ED return
visits has become one of the principal concerns. In this light and in the spirit of taking part
of this concert, we intended to identify respiratory conditions and associated comorbidities
most likely to result in a return visit among children discharged home from the ED. For this,
special attention was given to univariate and multivariate analyses and machine learning
consideration. The univariate study was performed in analyzing the summary statistics of
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the eligible population. The multivariate analysis was conducted in using a nested mixed
effects model, with the aim of modeling the return to ED within 72 hours such that the
ED facilities are random intercepts and patients nested within the facilities. The machine
learning consideration was executed by hyper-tuning 15 classifiers.
It resulted from the study that unexpected return visits to the ED among children undergoing
respiratory is statistically and significantly associated with conditions such as Acute bron-
chiolitis [odds ratio and 95% confidence interval: 1.39 (1.35, 1.44)], pneumonia [1.22 (1.18,
1.27)], and asthma [1.07 (1.04, 1.10)]. In addition, we found that over 80% of non-respiratory
comorbid classes of diseases are associated with increased risk of return visits.
Furthermore, we found that machine learning models are not imperatively suited for pre-
dicting return visits as these could be influenced by factors that are related to behavioral
patterns of the families with the patients.
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Table 3.2: Univariate Summary Statistics (USS)
Variable Levels
No return
visit
Had return
visit
Chi-
squared
N (%) N (%) p value
Resource Utilization, Medications, and Season
ED length of stay (hours)
[0,4) 934976 (85.15) 30572 (83.21)
< 0.001
[4,8) 106997 (9.74) 4215 (11.47)
[8,16) 41631 (3.79) 1394 (3.79)
[16,24) 14428 (1.31) 558 (1.52)
Previous ED Visit
0 674715 (61.45) 17544 (47.75)
< 0.001
1 252210 (22.97) 9477 (25.80)
2 99013 (9.02) 4567 (12.43)
3 or more 72094 (6.57) 5151 (14.02)
Previous hospitalizations (prior
6 months)
No 1047164 (95.37) 34104 (92.83)
< 0.001
Yes 50868 (4.63) 2635 (7.17)
Has History Of Return Visit
No 1038850 (94.61) 32619 (88.79)
< 0.001
Yes 59182 (5.39) 4120 (11.21)
Free-standing pediatric ED
No 679870 (61.92) 21307 (58.00)
< 0.001
Yes 418162 (38.08) 15432 (42.00)
Number of medications greater
than 90th percentile
No 1060102 (96.55) 34853 (94.87)
< 0.001
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Yes 37930 (3.45) 1886 (5.13)
Season
Winter 350208 (31.89) 12114 (32.97)
< 0.001
Spring 284611 (25.92) 9628 (26.21)
Summer 177002 (16.12) 6081 (16.55)
Fall 286211 (26.07) 8916 (24.27)
Comorbid Diagnoses
Certain infectious and parasitic
diseases (A00-B99)
No 1008346 (91.83) 33356 (90.79)
< 0.001
Yes 89686 (8.17) 3383 (9.21)
Neoplasms (C00-D49)
No 1096685 (99.88) 36653 (99.77)
< 0.001
Yes 1347 (0.12) 86 (0.23)
Diseases of the blood and blood-
forming organs and certain disor-
ders involving the immune mech-
anism (D50-D89)
No 1091372 (99.39) 36275 (98.74)
< 0.001
Yes 6660 (0.61) 464 (1.26)
Endocrine, nutritional and
metabolic diseases (E00-E89)
No 1083629 (98.69) 36060 (98.15)
< 0.001
Yes 14403 (1.31) 679 (1.85)
Mental, Behavioral and Neu-
rodevelopmental disorders (F01-
F99)
No 1083399 (98.67) 36171 (98.45)
< 0.001
Yes 14633 (1.33) 568 (1.55)
Diseases of the nervous system
(G00-G99)
No 1069382 (97.39) 35721 (97.23)
0.058
Yes 28650 (2.61) 1018 (2.77)
Diseases of the eye and adnexa
(H00-H59)
No 933720 (85.04) 31914 (86.87)
< 0.001
Yes 164312 (14.96) 4825 (13.13)
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Diseases of the circulatory sys-
tem (I00-I99)
No 1091760 (99.43) 36416 (99.12)
< 0.001
Yes 6272 (0.57) 323 (0.88)
Diseases of the digestive system
(K00-K95)
No 1055944 (96.17) 34980 (95.21)
< 0.001
Yes 42088 (3.83) 1759 (4.79)
Diseases of the skin and subcu-
taneous tissue (L00-L99)
No 1069817 (97.43) 35611 (96.93)
< 0.001
Yes 28215 (2.57) 1128 (3.07)
Diseases of the musculoskele-
tal system and connective tissue
(M00-M99)
No 1077523 (98.13) 36100 (98.26)
0.076
Yes 20509 (1.87) 639 (1.74)
Diseases of the genitourinary sys-
tem (N00-N99)
No 1082372 (98.57) 36051 (98.13)
< 0.001
Yes 15660 (1.43) 688 (1.87)
Pregnancy, childbirth and the
puerperium (O00-O9A)
No 1097151 (99.92) 36689 (99.86)
< 0.001
Yes 881 (0.08) 50 (0.14)
Certain conditions originating in
the perinatal period (P00-P96)
No 1094492 (99.68) 36612 (99.65)
0.467
Yes 3540 (0.32) 127 (0.35)
Congenital malformations, de-
formations and chromosomal ab-
normalities (Q00-Q99)
No 1091627 (99.42) 36481 (99.30)
0.004
Yes 6405 (0.58) 258 (0.70)
Injury, poisoning and certain
other consequences of external
causes (S00-T88)
No 1064455 (96.94) 35840 (97.55)
< 0.001
Yes 33577 (3.06) 899 (2.45)
Surgical Procedures
Auditory surgery (CPT4: 69000-
69979)
No 1096616 (99.87) 36698 (99.89)
0.401
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Yes 1416 (0.13) 41 (0.11)
Cardiovascular surgery (CPT4:
33010-37799)
No 1092786 (99.52) 36413 (99.11)
< 0.001
Yes 5246 (0.48) 326 (0.89)
Digestive surgery (CPT4: 40490-
49999)
No 1096760 (99.88) 36698 (99.89)
0.875
Yes 1272 (0.12) 41 (0.11)
Integumentary surgery (CPT4:
10030-19499)
No 1096378 (99.85) 36654 (99.77)
< 0.001
Yes 1654 (0.15) 85 (0.23)
Musculoskeletal surgery (CPT4:
20100-29999)
No 1096460 (99.86) 36705 (99.91)
0.014
Yes 1572 (0.14) 34 (0.09)
Urinary/Reproductive system
surgery (CPT4: 50010-58999)
No 1095484 (99.77) 36540 (99.46)
< 0.001
Yes 2548 (0.23) 199 (0.54)
Table 3.3: USS Continuation
Variable Levels
No return
visit
Had return
visit
Chi-
squared
N (%) N (%) p value
Demographics
Age, y
[0, 5) 630446 (57.42) 24049 (65.46)
< 0.001[5, 12) 317500 (28.92) 8389 (22.83)
[12 or older) 150086 (13.67) 4301 (11.71)
Sex
Female 510656 (46.51) 16632 (45.27)
< 0.001
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Male 587376 (53.49) 20107 (54.73)
Payer
Commercial 256720 (23.38) 7967 (21.69)
< 0.001
Medicare or
Medicaid
631730 (57.53) 21966 (59.79)
Other
governmental
24822 (2.26) 827 (2.25)
Self-Pay 66465 (6.05) 1987 (5.41)
Others 118295 (10.77) 3992 (10.87)
Race and/or ethnicity
Caucasian 465203 (42.37) 15563 (42.36)
< 0.001
African
American
343185 (31.25) 11165 (30.39)
Hispanic 76179 (6.94) 2564 (6.98)
Asian Pacific
Islander
13668 (1.24) 486 (1.32)
Native
American
25517 (2.32) 1059 (2.88)
Other 174280 (15.87) 5902 (16.06)
Respiratory conditions
Acute nasopharyngitis [common
cold] (J00)
No 1068164 (97.28) 35829 (97.52)
0.005
Yes 29868 (2.72) 910 (2.48)
Acute sinusitis (J01)
No 1089198 (99.20) 36531 (99.43)
< 0.001
Yes 8834 (0.80) 208 (0.57)
Acute pharyngitis (J02)
No 872131 (79.43) 30176 (82.14)
< 0.001
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Yes 225901 (20.57) 6563 (17.86)
Acute tonsillitis (J03)
No 1048445 (95.48) 35385 (96.31)
< 0.001
Yes 49587 (4.52) 1354 (3.69)
Acute laryngitis and tracheitis
(J04)
No 1096471 (99.86) 36686 (99.86)
0.972
Yes 1561 (0.14) 53 (0.14)
Acute obstructive laryngitis
[croup] and epiglottitis (J05)
No 1038772 (94.60) 34513 (93.94)
< 0.001
Yes 59260 (5.40) 2226 (6.06)
jAcute upper respiratory infec-
tions of multiple and unspecified
sites (J06)
No 683091 (62.21) 23327 (63.49)
< 0.001
Yes 414941 (37.79) 13412 (36.51)
Influenza due to certain identi-
fied influenza viruses (J09-J11)
No 1057642 (96.32) 35543 (96.74)
< 0.001
Yes 40390 (3.68) 1196 (3.26)
Viral pneumonia, not elsewhere
classified (J12)
No 1096551 (99.87) 36649 (99.76)
< 0.001
Yes 1481 (0.13) 90 (0.24)
Bacteria and Other
Pneumonia(J13-J18)
No 1044872 (95.16) 34173 (93.02)
< 0.001
Yes 53160 (4.84) 2566 (6.98)
Acute bronchitis (J20)
No 1073771 (97.79) 36112 (98.29)
< 0.001
Yes 24261 (2.21) 627 (1.71)
Acute bronchiolitis (J21)
No 1038129 (94.54) 33336 (90.74)
< 0.001
Yes 59903 (5.46) 3403 (9.26)
Vasomotor and allergic rhinitis
(J30)
No 1073407 (97.76) 36226 (98.60)
< 0.001
Yes 24625 (2.24) 513 (1.40)
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Chronic rhinitis, nasopharyngitis
and pharyngitis (J31)
No 1094025 (99.64) 36647 (99.75)
< 0.001
Yes 4007 (0.36) 92 (0.25)
Chronic sinusitis (J32)
No 1081559 (98.50) 36290 (98.78)
< 0.001
Yes 16473 (1.50) 449 (1.22)
Chronic diseases of tonsils and
adenoids (J35)
No 1095590 (99.78) 36680 (99.84)
0.015
Yes 2442 (0.22) 59 (0.16)
Nasal Polyp Other Unspec-
ified Disorders Nose Nasal
Sinuses(J33-J34)
No 998423 (90.93) 33687 (91.69)
< 0.001
Yes 99609 (9.07) 3052 (8.31)
Peritonsillar abscess (J36)
No 1097063 (99.91) 36664 (99.80)
< 0.001
Yes 969 (0.09) 75 (0.20)
Other diseases of upper respira-
tory tract (J39)
No 1096467 (99.86) 36698 (99.89)
0.1387
Yes 1565 (0.14) 41 (0.11)
COPD (J40-J44)
No 1073593 (97.77) 36053 (98.13)
< 0.001
Yes 24439 (2.23) 686 (1.87)
Asthma (J45)
No 896664 (81.66) 30209 (82.23)
0.006
Yes 201368 (18.34) 6530 (17.77)
Acute respiratory distress syn-
drome (J80)
No 1096515 (99.86) 36688 (99.86)
1.000
Yes 1517 (0.14) 51 (0.14)
Suppurative and nectrotic condi-
tions of lower respiratory tract
(J85-J86)
No 1097105 (99.92) 36710 (99.92)
0.791
Yes 927 (0.08) 29 (0.08)
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Pleural effusion, plague, and
other pleural conditions (J90-
J92, J94)
No 1096757 (99.88) 36686 (99.86)
0.140
Yes 1275 (0.12) 53 (0.14)
Intraoperative and postprocedu-
ral complications and disorders
not classified elsewhere (J95)
No 1096176 (99.83) 36638 (99.73)
< 0.001
Yes 1856 (0.17) 101 (0.27)
Other diseases of the respiratory
system (J98-J99)
No 1082079 (98.55) 36175 (98.46)
0.203
Yes 15953 (1.45) 564 (1.54)
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Table 3.4: Results of the Mixed Effects Models(MEM)
Variable Levels Odds Ratio p value
ED Length of stay (hours)
[0,4) Reference
< 0.001
[4,8) 1.131 (1.091, 1.173)
[8,16) 1.149 (1.070, 1.235)
[16,24) 1.304 (1.181, 1.440)
Previous ED Visit
0 Reference
< 0.001
1 1.367 (1.332, 1.403)
2 1.606 (1.551, 1.663)
3 or more 2.244 (2.161, 2.331)
Previous hospitalizations (prior 6
month)
Yes 1.202 (1.152, 1.255) < 0.001
Has History Of Return Visit Yes 1.158 (1.114, 1.204) < 0.001
Number of medications greater than
90th percentile
Yes 1.399 (1.33, 1.471) < 0.001
Season
Winter Reference
Spring 0.988 (0.961, 1.015) 0.381
Summer 1.014 (0.982, 1.047) 0.393
Fall 0.928 (0.902, 0.955) < 0.001
Comorbid Diagnoses
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Diseases of the blood and blood-
forming organs and certain disorders in-
volving the immune mechanism (D50-
D89)
Yes 1.706 (1.528, 1.905) < 0.001
Pregnancy, childbirth and the puer-
perium (O00-O9A)
Yes 1.511 (1.127, 2.025) 0.006
Neoplasms (C00-D49) Yes 1.385 (1.100, 1.744) 0.006
Diseases of the circulatory system (I00-
I99)
Yes 1.241 (1.080, 1.427) 0.002
Diseases of the genitourinary system
(N00-N99)
Yes 1.233 (1.131, 1.343) < 0.001
Mental, Behavioral and Neurodevelop-
mental disorders (F01-F99)
Yes 1.184 (1.083, 1.296) < 0.001
Diseases of the digestive system (K00-
K95)
Yes 1.134 (1.077, 1.194) < 0.001
Diseases of the skin and subcutaneous
tissue (L00-L99)
Yes 1.120 (1.050, 1.194) 0.001
Endocrine, nutritional and metabolic
diseases (E00-E89)
Yes 1.112 (1.019, 1.214) 0.017
Certain infectious and parasitic diseases
(A00-B99)
Yes 1.102 (1.062, 1.143) < 0.001
Diseases of the nervous system (G00-
G99)
Yes 1.100 (1.026, 1.179) 0.007
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Injury, poisoning and certain other con-
sequences of external causes (S00-T88)
Yes 0.810 (0.754, 0.870) < 0.001
Diseases of the eye and adnexa (H00-
H59)
Yes 0.804 (0.779, 0.830) < 0.001
Surgical Procedures
Integumentary surgery (CPT4: 10030-
19499)
1.832 (1.461, 2.296) < 0.001
Urinary/Reproductive system surgery
(CPT4: 50010-58999)
1.603 (1.381, 1.860) < 0.001
Cardiovascular surgery (CPT4: 33010-
37799)
1.491 (1.324, 1.678) < 0.001
Digestive surgery (CPT4: 40490-49999) 0.725 (0.526, 0.999) < 0.001
Table 3.5: MEM Continuation
Variable Level Odds ratio (95% CI) p value
Age, y
[0, 5) Reference
< 0.001[5, 12) 0.782 (0.760, 0.804)
[12 or older) 0.816 (0.786, 0.848)
Payer
Commercial Reference
Medicare or
Medicaid
1.127 (1.092, 1.163) < 0.001
Other
governmental
1.142 (1.059, 1.232) < 0.001
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Self-Pay 1.042 (0.988, 1.098) 0.128
Others 1.202 (1.149, 1.257) < 0.001
Race and/or ethnicity
Caucasian
African American 0.940 (0.912, 0.969) < 0.001
Hispanic 0.964 (0.919, 1.011) 0.134
Asian Pacific
Islander
1.054 (0.959, 1.159) 0.274
Native American 0.928 (0.835, 1.031) 0.165
Other 1.017 (0.982, 1.054) 0.339
Sex
Female Reference
Male 1.025 (1.003, 1.047) 0.024
Respiratory risk factors
Peritonsillar abscess (J36) Yes 2.266 (1.775, 2.892) < 0.001
Viral pneumonia, not elsewhere
classified (J12)
Yes 1.436 (1.155, 1.785) 0.001
Acute bronchiolitis (J21) Yes 1.390 (1.332, 1.449) < 0.001
Bacteria and Other
Pneumonia(J13-J18)
Yes 1.273 (1.216, 1.333) < 0.001
Other respiratory conditions
Acute pharyngitis (J02) Yes 0.948 (0.915, 0.982) 0.003
Asthma (J45) Yes 0.924 (0.894, 0.956) < 0.001
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Acute upper respiratory infec-
tions of multiple and unspecified
sites (J06)
Yes 0.910 (0.885, 0.936) < 0.001
Acute nasopharyngitis [common
cold] (J00)
Yes 0.907 (0.845, 0.975) < 0.001
Acute tonsillitis (J03) Yes 0.896 (0.844, 0.950) < 0.001
COPD (J40-J44) Yes 0.888 (0.820, 0.961) 0.003
Influenza due to certain identi-
fied influenza viruses (J09-J11)
Yes 0.881 (0.828, 0.939) < 0.001
Nasal Polyp Other Unspec-
ified Disorders Nose Nasal
Sinuses(J33-J34)
Yes 0.875 (0.840, 0.911) < 0.001
Chronic sinusitis (J32) Yes 0.859 (0.779, 0.946) < 0.001
Acute bronchitis (J20) Yes 0.819 (0.754, 0.890) < 0.001
Acute sinusitis (J01) Yes 0.768 (0.667, 0.884) < 0.001
Chronic diseases of tonsils and
adenoids (J35)
Yes 0.724 (0.558, 0.939) 0.015
Vasomotor and allergic rhinitis
(J30)
Yes 0.683 (0.624, 0.748) < 0.001
Chronic rhinitis, nasopharyngitis
and pharyngitis (J31)
Yes 0.665 (0.540, 0.820) < 0.001
Intraoperative and postprocedu-
ral complications and disorders
not classified elsewhere (J95)
Yes 0.641 (0.491, 0.837) 0.001
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Table 3.6: Performance of Machine Learning Models
Model Name AUC Values
DCT 0.514
KNN 0.532
GNB 0.535
MNB 0.532
CNB 0.546
MLR 0.548
RRC 0.546
LCSGD 0.553
PAC 0.534
SVC 0.544
RF 0.546
ERT 0.542
GBT 0.558
EGBT 0.645
MLP 0.519
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4 General Pediatric Models for
Understanding and Predicting Prolonged
Hospital Length of Stay
The impact of the deterioration in the health of a child requiring hospitalization on the family
is multifaceted. It encompasses social, economic, and psychological impressions. To alleviate
those burdens, considerable efforts have been deployed, with the ultimate goal of improving
the healthcare system, the organizational management of modern hospitals and improving
the quality of care delivered to patients. Some pediatric hospitals address these concerns by
creating departments such as Child Life to improve pediatric patients, especially that of the
young child. The length of stay (LOS) in the emergency department (ED) patients has been
found to be a top priority for hospitals and health systems.
Traditionally, ED length of stay (LOS) has been used as an accurate metric to assess the
efficiency of ED management, patient quality, patient quality of care, and functional evalu-
ation [78], [79]. In fact, it has generally been accepted that shorter LOS is associated with
more efficient and effective care [80]. Based on the existing standards, it has been suggested
that an appropriate median ED holding time should be of 2.0 hours for a hospital bed (1.5
hours for an intensive care unit (ICU)) [81]. For [82], patients presenting to the ED should
receive a decision in a maximum of 6 hours after admission to the ED and leave ED at this
time. The shorter a patient stays in the ED, the smaller the chance of developing infections
is [79]. Also, reduced ED LOS is associated with decreased mortality, drastic reduction of
the social costs, and financial burdens not only on patients but also on medical services [83],
[84]. Furthermore, reduced LOS can avoid unnecessary expenses and free up beds for other
critically ill patients.
In contrast, longer ED LOS can result in exposing patients to serious healthcare-acquired
infections, higher mortality rates, and imposing noticeable increase in the total social and
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financial related costs. The impact of prolonged length of stay transcends the child’s expe-
rience to that of the family and the hospital facility itself. Longer length of stay may result
in reduced working hours of a parent or guardian, lost productivity at work, and increased
psychological and financial burden on the family. Parents struggle to pay for prolonged care,
which has an impact on their current and future financial security that in turn affects their
children. A 3-year study of hospital resource utilization related to childhood cancer from
2005 found the cumulative charges reaching $16 million, which is about $100,000 per child
in the study [85]. In addition, 50% of those charges were in the first four and a half months
of diagnosis and those charges surprisingly were distributed among only 12.7% of patients
[85]. These patients had worse diagnoses and underwent a multitude of treatments. Parents
of children with a cancer diagnosis, even with insurance, accrue a significant bill to pay
for the treatment. The children themselves are likely to endure difficult mental health and
physical challenges as their LOS increases. In addition, providers and hospital facilities are
more likely to experience revenue leakage as well as challenges with adjudicating medical
claims for treatment offered. It is therefore imperative for the hospitalized child, the family,
providers, and the hospital to reduce unnecessarily prolonged LOS.
One of the most significant issues of ED prolonged LOS is overcrowding. ED overcrowding
has recently become a worldwide concern. ED overcrowding may result in creating many
problems patients and staff, increasing the waiting times and the ED resource utilization,
augmenting the length of stay, portending to an increase of errors and patient mortality, and
inflicting serious financial losses to hospitals [86], [87], [88].
Several studies have been conducted to determine risk factors of longer LOS. Internal and
external factors such as patient characteristics, ED staffing, health care providers, time of
patients arrival, diagnostic methods as well as hospital resource utilization, allocation, and
administration have strongly been associated with ED prolonged length of stay [81], [89], [87],
[79]. The impact of malnutrition [90], hyponatremia [91], febrile neutropenia [92], clinical
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pathways [84], [93] and weekend admission [94] on hospital length of stay are among the
studies conducted with the ambition to well understand eventual factors that contribute to
ED process times and patient care delays. An 18-year study from 2018 on a healthcare
center in Mexico assessed several sociodemographic and disease-specific differences for a
patient’s LOS [79] Oncology patients often require more hospitalizations during treatment
than patients with most other conditions. A study on the LOS of cancer patients in Brazil
explored the association between demographics and clinical attributes with LOS within the
first year of outpatient treatment [95].
In this study, we addressed the identification of novel risk factors for prolonged LOS using ad-
vanced statistical analysis and the prediction of patients most likely to experience prolonged
LOS using machine learning on a large multicenter electronic medical records database. The
goal of this study is to use data captured during the first 24 hours of admission to predict
patients with LOS greater than 2 weeks. The first 24 hours of hospitalization of a child
has yielded critical information to predict LOS [75]. Obviously, appropriate LOS depends
on diagnoses, severity of illness, and a host of complex clinical considerations. We chose a
2-week threshold because it is much greater than the average pediatric length of stay and
falls between the 90th and 95th percentile of general pediatric LOS.
4.1 Methods
Dataset, Clinical Admission, and Patient Encounter
This investigation was approved by the Institutional Review Board of CHOC Children’s
(#180857). A retrospective, population-based cohort study using the Cerner Health Facts
Database for the US-based patients is conducted. The Cener Health Facts database is a
de-identified patient database that provides records about patients coming from different
participating health institutions. The database contains time-stamped and sequenced infor-
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mation on pharmacy, laboratory, admission and billing data from all patient care locations.
In addition, Cener Health Facts database captures information demographic, hospital admis-
sions and discharge, and diagnostic procedures. As of 2018, the Health Facts database was
composed of records of more than 65 million patients provided by over 100 US healthcare
systems and over 650 facilities, more than 500 million encounters, approximately more than
500 million encounters, and 4.7 billion laboratory results. For the sake of confidentiality and
compliance with HIPAA privacy regulations, patient names are omitted and a unique iden-
tification number is assigned to each single patient, which is systematically available to all
the participating health institutions. Structurally, Cener Health Facts database stores and
retrieves data that is represented in smaller databases or tables. The database is available
to researchers at healthcare systems that contribute data to it. In 2020, the database was
upgraded and reconstituted as the Cerner Real World Data [96].
We retrieved all pediatric encounters (patients less than 18 years) from the database and
excluded encounters that occurred during the first 6 months of the very first encounter
for each hospital. This exclusion was necessary to ensure that encounters in each hospital
have a 6-month history for variables capturing patients’ history. Furthermore, we excluded
all encounters with LOS less than 24 hours to ensure that all qualifying encounters had a
minimum of 24 hours LOS and data within the first 24 hours of the admission. An additional
exclusion by hospital facility was carried out by excluding all facilities with less than 1000
encounters. The qualifying hospitals contributed data from different periods between 2001
and 2017. We calculated the average age of patients seen at each hospital and classified
those less than 18 years as free-standing pediatric hospitals.
We retrieved data on patient demographics, payer, medications administered during the
first 24 hours of admission, type of admission, and previous healthcare utilization 6 months
prior to the encounter start date. The variable race/ethnicity was divided into 6 groups:
Caucasian, Hispanic, Black/African American, Asian/Pacific Islander, Native American and
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Other/Unknwon. The type of insurance covering the patients were: commercial, govern-
mental (Medicare, Medicaid), other overnmental (Champus, etc), self pay, and otner. All
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
codes in the database were converted to the Tenth Revision (ICD-10-CM) using appropri-
ate translation tables and merged with the original ICD-10-CM data from the most recent
encounters. In order to automatically capture the largest number of the most prevalent pe-
diatric conditions as variables for the study, we retrieved the three-digit level of all ICD-10
diagnoses. This, however, introduced very rare encounters that may result in issues with
statistical separability as well as impact the value of corresponding findings. Consequently,
we set an a priori threshold for including a three-digit level diagnosis at an incidence rate
of 1%. In other words, only such diagnoses occur in 1% or greater was included. These
considerations also help in reducing the risk of modeling challenges due to statistical class
separability which may result in inflated effect sizes or inestimable parameters [97]. We
defined the outcome variable, prolonged LOS, as any LOS greater than 2 weeks.
Outliers in continuous variables may negatively affect statistical and machine learning mod-
els. We handled outliers excluding by records wherein the value of a continuous variable
was greater than the 99.5th percentile. We checked for multicollinearity between variables
by estimating the generalized variance inflation factor (GVIF) that measures the degree to
which correlation between variables in a model result in inflated variances [98] We set an a
priori threshold of 4 for the GVIF wherein all variables with GVIF greater than the threshold
is removed in a stepwise manner until all variables have GVIF less than 4 [75] We split the
data into two equal halves by patients.
Statistical Analysis
A two-stage statistical analysis study is implemented using ED LOS as outcome variable of
interest. First, we descriptively described the data via a summary statistics. Second, we built
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a statistical model for inference using a mixed effects logistic regression model where hospitals
were modeled as random intercepts with patients nested within them. Mixed models are an
extension of the traditional linear models which at its core incorporate random and fixed
effects. Mixed models (MM) are well suited describing analysis of clustered or longitudinal
nominal or ordinal response data [99]. They are most useful when working with hierarchical
data which often exude some degree of dependency (within-subjects designs /longitudinal
data). An example would be subjects being sampled from within doctors. MM systematically
accounts for within subjects variability thus, working around ANOVA assumption that data
points are independent of one another [100]. MM are also efficient at analyzing data that
are non-independent and correlated. MM address the correlation issue and does not violate
the linear model’s assumption- independence of observations.
To put MM at work, we started with a full model with all variables as well as 2 two-way
statistical interactions: (1) between age and diagnoses, and (2) between the number of
medications and diagnoses. The selection of these interaction terms was inspired the need
to capture difference in disease progression by age and by severity of illness. We selected
the number of medications administered during the first 24 hours as a proxy for severity of
illness since there are no standard measures of severity.
Given the fact numerous statistical models, such as mixed effects model, have serious prob-
lems with handling very complex and non-linear interactions among predictors themselves
as well as with the target variable, it is worth the efforts to trying other robust models.
Thus, to further the study, we used the extreme gradient boosting (XGBoost) to assess
higher level interactions beyond the 2-way statistical interactions(for example 3 or more)
considered in the mixed effects model. Extreme gradient boosting is a variant of of the
Gradient Boosting Machine. Virtually, XGBoost aims at using an ensemble of weak learners
that are sequentially trained in the sake of having a stronger classifier or regresser model.
A meta-optimization task was performed by tuning some hyperparameters, which make the
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ensemble training controllable. This was indeed done with cross validation technique for
assessing how the results of a model will perform on an unseen data. Table 4.1 displays the
values assumed by the involved hyperparameters.
Table 4.1: Parameter grid for hyperparameter tuning of the
extreme gradient boosting model
Hyperparameter Values Significance
Boosting operations/iterations 64 Number of boosting operations
is equivalent to the number of
trees built. We chose 64 based
on previous experience on the
minimum number of boosting
iterations required
Learning rate 0.2, 0.3, 0.5, 0.8 Relating to how fast the model
learns. Smaller values help to
prevent overfitting
Maximum tree depth 4, 6, 8 The depth of each tree which
controls the complexity of the
model and interactions explored
Minimum child weight 0, 1, 2, 4 Relating to how partitions are
made on a child node. Larger
values create more conservative
models
Gamma 0, 1, 2, 4 Relating to how leaf node
partitions with respect to
changes in loss. Larger values
result in more conservative
models
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Figure 4.1: LOS with respect to patient’s gender
Numerous metrics such as the area under the receiver characteristics curve (AUROC), the
area under the precision-recall curve (AUCPR), and the values of model sensitivity, positive
predictive value, negative predictive value, F1 score, and the number needed to evaluate (as
the number of patients that will be flagged at-risk before a true positive prediction) were
used to evaluate the performance of both the statistical mixed effects regression and machine
learning models.
4.2 Results
Exploratory Data Analysis : Free-standing Pediatric and Mixed Medical Facili-
ties
Sixty medical centers met the inclusion criteria for hospitals. Of the medical centers used in
this study, nine (9) were free-standing pediatric hospitals, with the remainder being mixed
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medical centers. The 9 free-standing pediatric hospitals contributed ∼51% of all encounters
in the study thereby accounting for the longest period and the greatest number of daily
pediatric admissions.
Exploratory Data Analysis: Length of Stay Class
A total of 700,00 patients with ∼1,000,000 encounters met the inclusion criteria for encoun-
ters. The rate of prolonged LOS was 5.0% across all patients and their encounters. The
mean age of the patients was 5 years. Interestingly from the data, we observed that female
patients account for ∼47.3% of LOS class 1 while male subjects were ∼54.1% of LOS class 2
(Figure 4.1). From the within group percentage of both LOS classes high cases of emergent
admissions were observed, with LOS 1 and LOS 2 accounting for 83.7% and 85% of the total
number of patients Figure 4.2.
Expectedly, the combination of commercial and governmental health insurance accounted
for over 60% of all patients coverage plans while 2.2% and 1.8% of the patients paid out of
pocket in both LOS classes (Figure 4.3). From the withing group percentage of patients, we
observed that there were nearly as many children as adults in LOS 1 with children account-
ing for ∼50.4% of all patients, whereas there was a 3/2 ratio of children to adults in LOS 2,
where adults account for ∼40.8% (Figure 4.4). Furthermore, we explored the ethnicity/race
distribution of the patients. Notably, patients with Caucasian background accounted for
approximately half of all races represented in both LOS classes. Patients of African descent
accounted for ∼20% of all patients. Strikingly, ∼20% of the subjects’ ethnicity were undis-
closed while patients of Hispanic, Asian, Native American origin accounting for ∼4%, ∼2%,
and ∼2% of all LOS 1 and LOS 2 subjects (Figure 4.5).
Descriptively (Table 4.5), we surprisingly found that apart from variables (11) including
Overweight and obesity (E66), Scoliosis (M41), Pervasive developmental disorders (F84),
Pneumonia, unspecified organism (J18), Other and unspecified soft tissue disorders, not
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Figure 4.2: LOS with respect to Emergent Admission
elsewhere classified (M79), Other symptoms and signs involving the circulatory and respi-
ratory system (R09), Fever of other and unknown origin (R50), Headache (R51), Liveborn
infants according to place of birth and type of delivery (Z38), Family history of other specific
disorders (Z83), and Personal risk factors, not elsewhere classified (Z91), there is existence a
significant (P < 0.001) association between the prevalence of prolonged LOS in emergency
department and the remaining variables which constitute the data set.
Multivariate Analysis : mixed effects model
In this retrospective multi-centered study, a mixed effects model (with hospitals as random
intercepts and patients nested within hospitals) was constructed to evaluate the association
between LOS and the involved independent variables in the ED settings. The results obtained
from MM are shown in Table 4.6. It was found that a statistically significant association
between such as variables patient demographics, healthcare utilization variables, certain
diagnoses without interactions, certain interactions between age and diagnoses, and certain
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Figure 4.3: LOS with respect to insurance cover
interactions between number of medications and diagnoses, and prolonged length of stay
exists.
Variables with no interaction(s)
Male patients were significantly more likely to have prolonged LOS with a 6.7% increase in
the odds. Compared to the baseline group of patients that have commercial health insur-
ance, patients that have governmental insurance (Medicare, Medcaid) or any other types
of government insurances (Champus, etc) have higher odds of experiencing prolonged LOS
with increases 35% and 21% respectively. Similarly, self-insured patients have 35% higher
odds of prolonged LOS compared to commercially insured patients. Patients that possess
other health insurance or coverage have 34% higher odds than the baseline group of pa-
tients. Compared to Caucasian, patients from other races/ethic groups have higher odds
of experiencing prolonged LOS with increases of approximately 0.04-, 11-, 11.20-, 15% for
Asian/Pacific Islander, Hispanic, Other/Unknown, and Native American respectively. We
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Figure 4.4: LOS with respect to patient’s age
also found that patient’s maximum of length of stay in the last 6 months, emergency ad-
mission status and past readmission history are significantly associated with the odds of
extended length of stay in ED. Along with being with such significant associations, they all
have an increase in odds of having a prolonged LOS ranging from approximately from 4%
to and 67% with maximum previous length of stay(last 6 months) and emergency admission
variables assuming respectively the smallest and largest increases in odds. In contrast, pa-
tient’s history of ED visits has a decrease in odds of causing a prolonged length of stay. The
Free-standing pediatric hospital variable appears to not be a significant factor to prolonged
LOS.
Certain diagnoses were significantly associated with prolonged LOS. These diagnoses include
Lymphoid leukemia (C91), Type 1 diabetes mellitus (E10), Suppurative and unspecified
otittis media(H66), Pneumonia, unspecified organism (J18), Disorders of newborn related
to short gestation and low birth weight, not elsewhere classified (P07), Family history of
certain disabilities and chronic diseases (leading to disablement) (Z82), Personal history of
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Figure 4.5: LOS with respect to race/ethnicity
other diseases and conditions (Z87), Pervasive developmental disorders (F84), and Sleep
disorders (G47). The decrease in odds associated with these conditions are greater than 18-
and less than 72%. On the other hand, the remaining conditions are risk factors that are
highly associated with extended length of stay with an increase of odds ranging from 3% to
445%. Variables with interaction(s)
An interaction arises if there is an eventual relationship among two or more variables. [101]
defines a statistical interaction as a scenario where the relation between a predictor and a
target variable depends on another independent variable, named as a moderator. Our mixed
effects model gives us a mathematical model that we can we use to estimate the probability
of a patient stay more than expected in the hospital given certain independent variables. For
example, suppose that we have three predictors, X, Z, and XZ. The model could roughly be
expressed as:
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log(
π
1− π
) = α0 + α1X + α3Z + α3XZ (4.1)
wherein α0, α1, α2, α3 are the coefficients of the model. The statistical significance of the
interaction coefficient α3 informs about the association between X and the probability that
the outcome variable Y be equal to 1 depends on the predictor Z.
Table 4.8 and Table 4.9 show the results of two separate multivariate analyses. First, we
chose to discuss the results from the interaction effects between two main effects and the
remaining independent variables in the model: one for age of patient and the other one is for
the number of medications administered to a patient. In this process, we not only examine
the significance of the risk factor(s), but also the strength of the association. Then, the
odd ratios is calculated for each effect present in the model. As mentioned earlier, this is
conducted by deploying a mixed effects model.
Statistical interactions with age
Table 4.8 describes the main effects of age and those of the other existing independent vari-
ables. The results show that each main effect in the model is statistically and significantly (P
< 0.001) associated with prolonged LOS. Table 4.8 also shows that the interaction between
the factor age and any other factor is strongly associated with staying in ED more than 2
weeks. In addition, we notice that the main effects Age, Pervasive developmental disorders
(F84), Asthma (J45), Other disorders of urinary system (N39), Sleep disorders (G47), Con-
vulsions, Not elsewhere classified (R56), and Obstructive and reflux uropathy (N13), with
negative coefficients are less likely to be important risk factors of prolonged length of stay.
This tells us that in the absence of statistical interactions with medical conditions a patient
is undergoing, older patients are less likely to have prolonged length of stay. In contrast,
without any interaction, patients that suffer from Streptococcus, Staphylococcus, and En-
terococcus as the cause of diseases classified elsewhere (B95), Other anemias (D64), Major
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depressive disorder, single episode (F32), and Attention-deficit hyperactivity disorders (F90)
are more likely to stay longer in hospital in the case their condition worsens.
From the second part of Table 4.8, we can easily see that the interactions between age and
conditions such as Pervasive development disorders (F84), Asthma (J45), Certain disorders
of the urinary system(N39), Streptococcus, Staphylococcus, and Enterococcus diseases clas-
sified elsewhere (B95), Certain functional intestinal disorders (K59), and Sleep disorders
(G47) are statistically significant to the prolonged length of stay in hospital. In addition, we
can notice that these conditions interacting with age produce some positive effects on the
length of stay. This implies that patients that face the deterioration of their health, based
on the evolution of these conditions, are more likely to stay longer than expected in hospital.
For the sake of understanding the concept of 2-way statistical interaction between age and
diagnoses or medical conditions, let us consider some graphical representations. Do note that
age and diagnoses are a continuous variable and a dichotomous variable respectively. Thus,
the two-way interaction between age and a particular diagnosis fit separate regression lines
(on the log-odds scale) for the effects of age for the groups with and without the condition.
A positive/negative interaction effect reflects a higher/lower slope for the line depicting the
effect of age for the group with the condition compared to the group without. The intercepts
of the lines are functions of the main effects that in combination with the slopes can produce
different scenarios (non-parallel non-intersecting lines within the range of values of age with
various slopes or non-parallel intersecting lines within the range of values of age with various
slopes). These scenarios are displayed (on the probability scale).
Figure 4.6 displays the statistical 2-way interaction between age and 4 diagnoses with positive
effects. The plots in Figure 4.6 show the predicted probability of prolonged length of stay
with respect to patients’ age. In the top left plot, we observe that the directions of the
effects size of the age between the level of the diagnosis are opposite. Second, we notice the
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presence of a statistical interaction between age and the Pervasive development disorders
(F84). Such an interaction is sustained by the intersection point between the two graphs.
Third, we can deduce that younger patients that do not suffer from Pervasive development
disorders (F84) are more likely to have a prolonged length of stay than patients that do not
have such a condition. Fourth, we remark that older patients with this condition have longer
length of stay. The right top plot is about two non-parallel lines depicting the level of the
asthma diagnosis. Since the two lines are not parallel, we can say that they will certainly
intersect at a certain age greater than 17. As with the previous graph, we can see that the
direction of the effects size of the age among patients with asthma and those with no-asthma
are opposite. It results from this that older patients with asthma conditions have higher
chance to have a prolonged length of stay. The left bottom plot shows that patients with
certain disorders of the urinary system(N39) are more likely to have a longer length of stay
once they get older. The right bottom graph indicates that the interaction associated with
infections due to Streptococcus, staphylococcus, and enterococcus(B95) was insufficient to
change the trend imposed by the main effects of age even though the direction of the effect
size of the interaction term was positive.
Statistical interactions could also have negative effect sizes. The second part of Table 4.8
shows some examples where the coefficients of condition-age interaction are negative values.
Arranged in decreasing order of the magnitude, the involved conditions in our study that have
negative interaction effect sizes with age include Attention-deficit hyperactivity disorders
(F90), Major depressive disorder, single episode (F32), Obstructive and reflux uropathy
(N13), Convulsions, not elsewhere classified (R56), and Other anemias (D64). Figure 4.7
represents the plots of some statistical interactions(with negative interaction effect sizes)
between age and the top 4 conditions. In the top left graph, the predicted probability length
of stay is displayed in terms of the age of the patients. From this graph, we can see that
the direction of the effects size of the age among patients that suffer from attention-deficit
71
hyperactivity disorders (F90) condition and those who do not have the so-called condition are
opposite. We can then notice an existing interaction between the two level of the attention-
deficit hyperactivity disorders (F90) condition. We can also notice that younger patients
with the attention-deficit hyperactivity disorders (F90) condition have higher probability of
having longer length of stay. A reverse scenario is seen with older patients. Similar findings
are displayed in the top right graph, with the exception that among the patients that do not
have the conditions, the predicted probability of longer LOS is much smaller in this case.
The bottom two graphs present the almost the same features in the direction of direction of
the effects size of the age among patients that suffer from Obstructive and reflux uropathy
(N13) and Convulsions, not elsewhere classified (R56). However, it should be highlighted
that patients with these two mental health conditions tend to have longer length of stays than
their peers. The graphs were interpolated cutting across ages younger than the minimum
age for diagnosis of these conditions. Obstructive and reflux uropathy (N13) and convulsions
(R56) had similar interactions with patients diagnosed with these conditions have reduced
odds for prolonged length of stay and further reduction in odds as patient age increases.
Statistical interactions with the number of medication administered during the
first 24 hours of hospitalization
Table 4.9 depicts the statistical interactions between the number of medications and the other
independent variables that are present in our model. It results from the first part of the table
that besides the factors Gastro-esophageal reflux disease (K21), Other functional intestinal
disorders (K59), Scoliosis (M41), Neonatal jaundice from other and unspecified causes (P59),
Transitory disorders of carbohydrate metabolism specific to newborn (P70), lack of expected
normal physiological development in childhood and adults (R62) and Personal risk factors,
not elsewhere classified (Z91), which accounts for of all the main effects in the model, the
remaining factors are significantly and statistically(P < 0.001) associated with prolonged
length of stay.
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The second part of Table 4.9 indicates the interaction effects between the number of medi-
cations and diagnoses. Strikingly, we found statistically significant interactions between the
number of medications and the factor diagnoses present in the study. Of these statistically
significant interactions, ∼ 20 percent have a negative interaction effect on the length of stay.
To better illustrate the effects of the 2-way statistical interactions between the number of
medications administered and different diagnoses, let us analyze the corresponding graphi-
cal representations. The scenarios are identical for the interaction between the number of
medicines that have been administered to the patients during the first 24 hours after admis-
sion and particular diagnoses. On the log-odds scale, the two-way interaction between the
number of medications and a diagnosis fits separate regression lines for the effects of number
of medications for the groups with and without the condition. A positive/negative interac-
tion effect reflects a higher/lower slope for the line depicting the effect of age for patients
under medications compared to the ones without medications. As previously stated, the
intercepts of the lines are functions of the main effects that in combination with the slopes
can produce different scenarios (non-parallel non-intersecting lines within the range of values
of age with various slopes or non-parallel intersecting lines within the range of values of age
with various slopes). Figure 4.8, and Figure 4.9 depict these scenarios on the probability
scale.
For this, we consider 4 top (diagnoses Liveborn infants according to place of birth and type of
delivery (Z38), Disorders of newborn related to long gestation and high birth weight (P08),
Viral and other specified intestinal infections (A08), and Acute bronchiolitis (J21)) that have
positive interaction diagnoses with number of medication factor (Figure 4.8). In the top left
graph where the predicted probability length of stay is displayed in terms of the number
of administered medications. We notice that with respect to small number of medications
administered in the first 24 hours after admission, newborns and children of other ages (who
were not born during the index encounter) have almost the same odds of prolonged length
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of stay. Opposed to this, as the number of administered medications increases within 24
hours, the odds for newborns exponentially increases. We also see that after 25 administred
medications, the odds for longer length of stay remains the same among liveborns. This
is indicated by the existence of the plateau reached after 25 administered medications. A
similar but less pronounced effect is seen for disorders of newborns related to the remaining
top 3 diagnoses.
Lastly, in the context of negative interaction effects, we chose the top 4 diagnoses which are
congenital malformations of cardiac septa (Q21), scoliosis (M41), congenital malformations
of the great arteries (Q25), and essential primary hypertension (I10). Figure 4.9 gives the
graphical representations of the corresponding interactions with the number of administered
medical. First, we notice that for smaller number of medications administered within 24
hours, regardless of the age, the patients have the same likelihood for longer length of stay.
In addition, it is shown that the effects size of the number of administered with 24 hours
among liverborns and among patients of other ages is the same are in the same direction. It
is also found patients with these conditions have reduced odds of prolonged length of stay
but the odds increases as the number of medication increase
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Figure 4.6: Positive interaction effect sizes with age
Figure 4.7: Negative interaction effect sizes with agewith age
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Figure 4.8: Positive interaction effect sizes with number of medications
Figure 4.9: Negative interaction effect sizes with number of medications
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Machine Learning Consideration
The amenable meta-optimization task achieves certain parameters that can be assumed as
the best performing set of parameters. In the best case, we have a maximum tree depth of
8, learning rate of 0.3, gamma of 4, and minimum child weight of 0. A full description of
the involved parameters is given in Table 4.1.
Model Performance
As mixed effects model returns a probability, a classification threshold of value 0.068 was
set since the beginning of the study. A value greater or equal to 0.068 will indicates that a
specific patient is at high risk of having a prolonged length of stay, a value below indicates
that the patient is not at high risk of staying more than expected. At this threshold and in
the absence of interventions, of 4 patients that are flagged as being at high risks only one of
them would have a prolonged length of stay. With the set threshold, the mixed effects model
achieved an AUROC of 0.887 (0.885, 0.889), and at a specificity of 0.900, the sensitivity
positive, positive predictive value, F1 score, and NNE were 0.667, 0.264, 0.380 and 3.782
respectively. The area under the precision recall curve was 0.513.
On the other hand, we observed a much higher performance of the chosen machine learning
model. The AUROC obtained by the extreme gradient boost model was 0.931 (0.930, 0.933).
At a specificity 0.900, the other metrics including sensitivity, positive predictive value, F1
score, and NNE assumed 0.786, 0.294, 0.428, and 3.398. An interpretation of this obtained
NNE values indicates that at the set threshold, 2 in 7 patients flagged at high risk for
prolonged length of stay would indeed have a prolonged length of stay in the absence of
interventions. The are under the precision-recall curve was 0.611.
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4.3 Discussion
In this work, a retrospective study was conducted to identify all of the clinically vital factors
that are statistically and significantly associated with hospital length of stay. For this,
a mixed effects model was used to extensively analyze the factors as well as a machine
learning algorithm for prediction. In this stride, interesting findings were observed. Some of
the findings are in full agreement with what clinically cited as factors to hospital prolonged
length of stay, and others are newly discovered. Newborns and neonatal population tend to
have the longest length of stay. These patients typically stay longer than 2 weeks. This is
expected in the case of admissions to the NICU after birth and within the first 28 days of
life. This finding reinforces the idea that neonatal population has very distinctive needs and
clinical presentation than the rest of the pediatric population. The proportion of neonatal
children with prolonged length of stay is 0.087 and significantly greater than their older peers
with a rate of 0.040. This creates a strong case for follow-up studies with focus specifically
on the neonatal population to find risk factors peculiar to neonates of which interventions
for improved quality of care may be developed.
The next set of findings is related to pediatric infectious diseases, cerebral palsy, cardiovas-
cular complications, neurological complications, and mental health conditions. We identified
an increased likelihood of prolonged length of stay in almost all cases of these diseases. But
the effect of mental health conditions is complicated by the age of the patient and the number
of medications administered (during the firs 24 hours of admission) as a proxy for severity
of overall illnesses. This indicates that conditions such as pneumonia, sepsis, cerebral palsy,
neurological conditions of the brain, abnormalities of heart beat, and complications after
surgery may be benefit from targeted interventions tailored to each condition. Interven-
tions relating to mental health conditions such as pervasive development disorders, major
depressive disorder, and attention-deficit hyperactivity disorder should consider the age of
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the patients as the risk of prolonged length of stay is modified by the age of the patient. In
addition, mental health conditions such as conduct disorders (F91), and reaction to severe
stress, and adjustment disorders (F43) have risk modified by the overall severity of illness as
measured by the number of medications being administered to these patients.
Conditions affecting the respiratory or pulmonary system such as bacterial pneumonia,
acute bronchiolitis, acute upper respiratory infections of multiple and unspecified sites (J06),
asthma, and respiratory conditions such as pulmonary collapse, disease of bronchus, and dis-
orders of the diaphragm may also be considered for targeted interventions aimed at reducing
the probability of unnecessarily prolonged length of stay.
A high model performance was achieved with the mixed effects model with statistics that in-
dicate potential usefulness if implemented electronically with associated interventions. But
we considered the large number of statistical interactions discovered in the mixed effects
model. These interactions were discovered simply by considering all 2-way statistical in-
teractions between diagnoses and both the age of the child and the number of medications
administered during the first 24 hours of hospitalization. This unusually high number of
interactions indicated that several other and potentially higher order interactions exist. We
explored this possibility bu considering deep extreme gradient boosting trees that explore
interactions in computationally feasible ways than can be achieved in equivalent regression
models. The resulting machine learning model obtained this way indicated that a statis-
tically significant improvement in model performance was achieved due to the presence of
higher order interactions. In other words, the factors driving pediatric hospital length of
stay are complex. Unfortunately, unlike regression models, machine learning models do not
readily lend themselves to the statistical interpretation of the complexities modelled within
them. Even attempts at explanations are obtained by searching for linear approximations.
However, pooling all the major findings of this study indicate the need of studies on specific
pediatric subpopulations within which specialty-dependent complexities may be modelled
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using corresponding mixed effects regressions algorithms. These subpopulations should in-
clude the neonatal, mental, and pediatric chronic conditions. These studies are likely to
reveal additional insights on the phenomena affecting hospital length of stay that may be
helpful in the development of specialty-based intervention protocols.
There were several limitations of this study. The challenges of conducting research with
electronic medical records of patients besets this study. The data were not collected for
the purpose of research and as such may contain random errors attributable to data entry
and storage, as well as differences in the standard of care across organizations. The use
of diagnosis codes is particularly nuanced but it is the best data available. Limitations
around differences in hospital administration were considered, and their effects mitigated by
the choice of mixed effects model that treated hospitals as random intercepts with patients
nested within them. Lastly, the implementation of either or both of the statistical and
machine learning model would require the use of highly skilled statisticians or data scientists
as well as robust information technology team that may be able to integrate statistical
and machine learning model in the electronic health records. Notwithstanding, this study
identified subgroups within the pediatric population that may be targeted for improvement in
quality of care that could result in reduction of unnecessary prolongation of hospitalization.
Future studies focusing specifically on the neonatal population is highly encouraged. In
addition, studies on pediatric mental health and chronic conditions may result in additional
and novel discoveries.
80
4.4 Summary
Prolonged length of stay (LOS) in medical facilities significantly increases the risk of healthcare-
associated infections (HAI) in pediatric and adult patients, often disrupting the access to
healthcare and overall health outcomes as well as increasing the financial burden on the en-
tire system. In this study, we designed and implemented a comprehensive study to identify
new clinical and demographic factors associated with prolonged length of stay (> 2 weeks)
among pediatric patients (aged 18 years and under) in a number of free-standing pediatric
and mixed medical facilities. For this, two approaches(univariate and multivariate) were
used to conduct statistical analyses. The univariate study helped us explore each variable
involved in the final data set, separately. The multivariate study was performed by building
a nested mixed effects model. This provided us with valid statistical inferences. The mixed
effects model accounts for the hierarchical structure of the data and assesses the statistical
significance and effect sizes of age, race/ethnicity, number of medications, medical family
history, presence of infection agents (fungi, bacteria,virus), cancer diagnoses and other con-
ditions as well as demographic and clinical variables. Furthermore, a stochastic gradient
boosting model was built for prediction to present ways to improve the care quality for
patients at high risk of prolonged length of stay, and avoid unnecessary expenses.
Our model identified 11 main effect variables with significant effects on the odds of prolonged
length of stay, 12 two-way interaction between age and certain conditions and 33 two-way
interaction between the number of medications and certain conditions. The AUC for the
mixed effects model was 0.89 and the extreme gradient booster attained AUC of 0.93.
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Table 4.2: Summary Statistics LOS Pediatrics
Variables Levels
LOS 1 week
or less
LOS > 1
week
p value
(chi-squared
or t-test)n (%) or
mean (sd)
n (%) or
mean (sd)
Sex
Female 225492 (47.35) 11553 (45.90)
< 0.001
Male 250737 (52.65) 13618 (54.10)
Payer
Commercial 152772 (32.08) 6917 (27.48)
< 0.001
Governmental
(Medicare,
Medicaid)
184555 (38.75) 11777 (46.79)
Other
Governmental
(Champus, etc)
18226 (3.83) 1001 (3.98)
Self-pay 10674 (2.24) 460 (1.83)
Other 110002 (23.10) 5016 (19.93)
Age AGE 5.93 (6.08) 4.56 (5.97) < 0.001
Race/Ethnicity
Caucasian 255472 (53.64) 12860 (51.09)
< 0.001
Hispanic 17889 (3.76) 895 (3.56)
Black/African
American
106198 (22.30) 5489 (21.81)
Asian/Pacific
Islander
8702 (1.83) 427 (1.70)
Native American 6920 (1.45) 425 (1.69)
Other/Unknown 81048 (17.02) 5075 (20.16)
Previous ED visits
(last 6mo)
prevEDcat0 363531 (76.34) 21140 (83.99)
< 0.001
prevEDcat1 112698 (23.66) 4031 (16.01)
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Maximum previous
length of stay (last
6mo)
- 1.52 (4.95) 4.33 (9.59) < 0.001
Number of
medications
Number Of Meds 2.23 (4.45) 11.16 (11.41) < 0.001
Number of
procedures
Number Of
Procedure
0.10 (0.51) 0.32 (1.01)
Emergent Admission
No 77436 (16.26) 3772 (14.99)
< 0.001
Yes 398793 (83.74) 21399 (85.01)
Readmission History
No 415569 (87.26) 19766 (78.53)
< 0.001
Yes 60660 (12.74) 5405 (21.47)
Free. . .
is Pediatric 0 236191 (49.60) 10269 (40.80)
< 0.001
is Pediatric 1 240038 (50.40) 14902 (59.20)
Viral and other
specified intestinal
infections (A08)
No 471186 (98.94) 25024 (99.42)
< 0.001
Yes 5043 (1.06) 147 (0.58)
Other sepsis (A41)
No 471695 (99.05) 24017 (95.42)
< 0.001
Yes 4534 (0.95) 1154 (4.58)
Viral infection of
unspecified site (B34)
No 470270 (98.75) 24789 (98.48)
< 0.001
Yes 5959 (1.25) 382 (1.52)
Streptococcus,
Staphylococcus, and
Enterococcus as the cause
of diseases classified
elsewhere (B95)
No 468183 (98.31) 23936 (95.09)
< 0.001
Yes 8046 (1.69) 1235 (4.91)
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Other bacterial agents as
the cause of diseases
classified elsewhere (B96)
No 469698 (98.63) 23888 (94.90)
< 0.001
Yes 6531 (1.37) 1283 (5.10)
Viral agents as the cause
of diseases classified
elsewhere (B97)
No 460317 (96.66) 24431 (97.06)
< 0.001
Yes 15912 (3.34) 740 (2.94)
Lymphoid leukemia (C91)
No 470587 (98.82) 24676 (98.03)
< 0.001
Yes 5642 (1.18) 495 (1.97)
Sickle-cell disorders (D57)
No 467694 (98.21) 24964 (99.18)
< 0.001
Yes 8535 (1.79) 207 (0.82)
Other anemias (D64)
No 466525 (97.96) 23589 (93.71)
< 0.001
Yes 9704 (2.04) 1582 (6.29)
Purpura and other
hemorrhagic conditions
(D69)
No 471560 (99.02) 24293 (96.51)
< 0.001
Yes 4669 (0.98) 878 (3.49)
Neutropenia (D70)
No 470668 (98.83) 24190 (96.10)
< 0.001
Yes 5561 (1.17) 981 (3.90)
Other disorders of white
blood cells (D72)
No 470868 (98.87) 24638 (97.88)
<0.001
Yes 5361 (1.13) 533 (2.12)
Type 1 diabetes mellitus (E10)
No 469772 (98.64) 25108 (99.75)
<0.001
Yes 6457 (1.36) 63 (0.25)
Overweight and obesity (E66)
No 469530 (98.59) 24848 (98.72)
0.110
Yes 6699 (1.41) 323 (1.28)
Volume depletion (E86)
No 449670 (94.42) 24209 (96.18)
< 0.001
Yes 26559 (5.58) 962 (3.82)
Other disorders of fluid,
electrolyte and acid-base
balance (E87)
No 461167 (96.84) 21606 (85.84)
< 0.001
Yes 15062 (3.16) 3565 (14.16)
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Major depressive disorder,
single episode (F32)
No 467416 (98.15) 24435 (97.08)
< 0.001
Yes 8813 (1.85) 736 (2.92)
Other anxiety disorders (F41)
No 466936 (98.05) 24511 (97.38)
< 0.001
Yes 9293 (1.95) 660 (2.62)
Reaction to severe stress,
and adjustment disorders
(F43)
No 469188 (98.52) 24576 (97.64) < 0.001
Yes 7041 (1.48) 595 (2.36)
Pervasive developmental
disorders (F84)
No 471185 (98.94) 24882 (98.85)
0.190
Yes 5044 (1.06) 289 (1.15)
ther disorders of
psychological development
(F88)
No 471193 (98.94) 24736 (98.27)
<0.001
Yes 5036 (1.06) 435 (1.73)
Attention-deficit
hyperactivity disorders
(F90)
No 464585 (97.55) 24456 (97.16)
<0.001
Yes 11644 (2.45) 715 (2.84)
Conduct disorders (F91)
No 471128 (98.93) 24527 (97.44)
< 0.001
Yes 5101 (1.07) 644 (2.56)
Epilepsy and recurrent
seizures (G40)
No 458341 (96.24) 24071 (95.63)
< 0.001
Yes 17888 (3.76) 1100 (4.37)
Sleep disorders (G47)
No 467634 (98.20) 24355 (96.76)
< 0.001
Yes 8595 (1.80) 816 (3.24)
Cerebral palsy (G80)
No 469797 (98.65) 24653 (97.94)
< 0.001
Yes 6432 (1.35) 518 (2.06)
Other disorders of brain (G93)
No 468274 (98.33) 23958 (95.18)
< 0.001
Yes 7955 (1.67) 1213 (4.82)
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Suppurative and unspecified
otitis media (H66)
No 468492 (98.38) 25038 (99.47)
< 0.001
Yes 7737 (1.62) 133 (0.53)
Essential (primary)
hypertension (I10)
No 471850 (99.08) 24404 (96.95)
< 0.001
Yes 4379 (0.92) 767 (3.05)
Other cardiac arrhythmias
(I49)
No 471856 (99.08) 24354 (96.75)
< 0.001
Yes 4373 (0.92) 817 (3.25)
Acute upper respiratory
infections of multiple and
unspecified sites (J06)
No 463782 (97.39) 24827 (98.63)
< 0.001
Yes 12447 (2.61) 344 (1.37)
Bacterial pneumonia, not
elsewhere classified (J15)
No 470220 (98.74) 24465 (97.20)
< 0.001
Yes 6009 (1.26) 706 (2.80)
Pneumonia, unspecified
organism (J18)
No 459014 (96.39) 24188 (96.09)
0.017
Yes 17215 (3.61) 983 (3.91)
Acute bronchiolitis (J21)
No 455023 (95.55) 24546 (97.52)
<0.001
Yes 21206 (4.45) 625 (2.48)
Asthma (J45)
No 432614 (90.84) 24200 (96.14)
<0.001
Yes 43615 (9.16) 971 (3.86)
Acute respiratory distress
syndrome (J80)
No 470722 (98.84) 24815 (98.59)
<0.001
Yes 5507 (1.16) 356 (1.41)
Respiratory failure, not
elsewhere classified (J96)
No 467134 (98.09) 22885 (90.92)
< 0.001
Yes 9095 (1.91) 2286 (9.08)
Other respiratory disorders
(J98)
No 465501 (97.75) 23391 (92.93)
< 0.001
Yes 10728 (2.25) 1780 (7.07)
Gastro-esophageal reflux
disease K21
No 460106 (96.61) 23263 (92.42)
< 0.001
Yes 16123 (3.39) 1908 (7.58)
Acute appendicitis (K35)
No 468467 (98.37) 25016 (99.38)
< 0.001
Yes 7762 (1.63) 155 (0.62)
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Other and unspecified
noninfective gastroenteritis
and colitis (K52)
No 466229 (97.90) 24407 (96.96)
< 0.001
Yes 10000 (2.10) 764 (3.04)
Paralytic ileus and intestinal
obstruction without hernia
(K56)
No 471611 (99.03) 24491 (97.30)
<0.001
Yes 4618 (0.97) 680 (2.70)
Other functional intestinal
disorders (K59)
No 457981 (96.17) 23391 (92.93)
<0.001
Yes 18248 (3.83) 1780 (7.07)
Cellulitis and acute
lymphangitis (L03)
No 465002 (97.64) 24720 (98.21)
<0.001
Yes 11227 (2.36) 451 (1.79)
Scoliosis (M41)
No 471283 (98.96) 24868 (98.80)
0.013
Yes 4946 (1.04) 303 (1.20)
Other and unspecified soft
tissue disorders, not
elsewhere classified (M79)
No 471580 (99.02) 24875 (98.82)
0.002
Yes 4649 (0.98) 296 (1.18)
Obstructive and reflux
uropathy (N13)
No 470817 (98.86) 24689 (98.09)
< 0.001
Yes 5412 (1.14) 482 (1.91)
Other disorders of urinary
system (N39)
No 468334 (98.34) 24484 (97.27)
< 0.001
Yes 7895 (1.66) 687 (2.73)
Disorders of newborn related
to short gestation and low
birth weight, not elsewhere
classified (P07)
No 469040 (98.49) 20310 (80.69)
< 0.001
Yes 7189 (1.51) 4861 (19.31)
Disorders of newborn related
to long gestation and high
birth weight (P08)
No 469849 (98.66) 24934 (99.06)
< 0.001
Yes 6380 (1.34) 237 (0.94)
Respiratory distress of
newborn (P22)
No 471406 (98.99) 22051 (87.60)
< 0.001
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Yes 4823 (1.01) 3120 (12.40)
Other respiratory conditions
originating in the perinatal
period (P28)
No 470980 (98.90) 21584 (85.75)
< 0.001
Yes 5249 (1.10) 3587 (14.25)
Cardiovascular disorders
originating in the perinatal
period (P29)
No 471319 (98.97) 22500 (89.39)
< 0.001
Yes 4910 (1.03) 2671 (10.61)
Neonatal jaundice from other
and unspecified causes (P59)
No 460905 (96.78) 21370 (84.90)
< 0.001
Yes 15324 (3.22) 3801 (15.10)
Transitory disorders of
carbohydrate metabolism
specific to newborn (P70)
No 472203 (99.15) 23975 (95.25)
< 0.001
Yes 4026 (0.85) 1196 (4.75)
Feeding problems of newborn
(P92)
No 471859 (99.08) 22596 (89.77)
< 0.001
Yes 4370 (0.92) 2575 (10.23)
Other conditions originating
in the perinatal period (P96)
No 470078 (98.71) 23245 (92.35)
< 0.001
Yes 6151 (1.29) 1926 (7.65)
Congenital malformations of
cardiac septa (Q21)
No 467151 (98.09) 22430 (89.11)
< 0.001
Yes 9078 (1.91) 2741 (10.89)
Congenital malformations of
great arteries (Q25)
No 472180 (99.15) 23090 (91.73)
< 0.001
Yes 4049 (0.85) 2081 (8.27)
Abnormalities of heart beat
(R00)
No 462313 (97.08) 23585 (93.70)
< 0.001
Yes 13916 (2.92) 1586 (6.30)
Cough (R05)
No 469262 (98.54) 24923 (99.01)
< 0.001
Yes 6967 (1.46) 248 (0.99)
Abnormalities of breathing
(R06)
No 446092 (93.67) 22427 (89.10)
<0.001
Yes 30137 (6.33) 2744 (10.90)
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Other symptoms and signs
involving the circulatory and
respiratory system (R09)
No 454487 (95.43) 24095 (95.73)
0.032
Yes 21742 (4.57) 1076 (4.27)
Abdominal and pelvic pain (R10)
No 460785 (96.76) 24550 (97.53)
<0.001
Yes 15444 (3.24) 621 (2.47)
Nausea and vomiting (R11)
No 454020 (95.34) 23773 (94.45)
<0.001
Yes 22209 (4.66) 1398 (5.55)
Other symptoms and signs
involving the digestive
system and abdomen (R19)
No 467938 (98.26) 24396 (96.92)
<0.001
Yes 8291 (1.74) 775 (3.08)
Symptoms and signs
involving emotional state
(R45)
No 468191 (98.31) 24591 (97.70)
<0.001
Yes 8038 (1.69) 580 (2.30)
Fever of other and unknown
origin (R50)
No 442745 (92.97) 23372 (92.85)
0.491
Yes 33484 (7.03) 1799 (7.15)
Headache (R51)
No 470066 (98.71) 24819 (98.60)
0.163
Yes 6163 (1.29) 352 (1.40)
Convulsions, not elsewhere
classified (R56)
No 462717 (97.16) 24526 (97.44)
0.011
Yes 13512 (2.84) 645 (2.56)
Lack of expected normal
physiological development in
childhood and adults (R62)
No 462776 (97.18) 23701 (94.16)
< 0.001
Yes 13453 (2.82) 1470 (5.84)
Symptoms and signs
concerning food and fluid
intake (R63)
No 462577 (97.13) 22677 (90.09)
< 0.001
Yes 13652 (2.87) 2494 (9.91)
Findings of drugs and other
substances, not normally
found in blood (R78)
No 471642 (99.04) 24431 (97.06)
< 0.001
Yes 4587 (0.96) 740 (2.94)
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Surgical operation and other
surgical procedures as the
cause of abnormal reaction of
the patient, or of later
complication, without
mention of misadventure at
the time of the procedure
(Y83)
No 471665 (99.04) 24491 (97.30)
< 0.001
Yes 4564 (0.96) 680 (2.70)
Place of occurrence of the
external cause (Y92)
No 463240 (97.27) 24308 (96.57)
< 0.001
Yes 12989 (2.73) 863 (3.43)
Encounter for observation
and evaluation of newborn
for suspected diseases and
conditions ruled out (Z05)
No 469243 (98.53) 23633 (93.89)
<0.001
Yes 6986 (1.47) 1538 (6.11)
Encounter for immunization
(Z23)
No 459579 (96.50) 23633 (93.89)
<0.001
Yes 16650 (3.50) 1538 (6.11)
Outcome of delivery (Z37)
No 468046 (98.28) 25032 (99.45)
<0.001
Yes 8183 (1.72) 139 (0.55)
Liveborn infants according to
place of birth and type of
delivery (Z38)
No 418130 (87.80) 22153 (88.01)
0.326
Yes 58099 (12.20) 3018 (11.99)
Encounter for other aftercare
and medical care (Z51)
No 462358 (97.09) 23759 (94.39)
<0.001
Yes 13871 (2.91) 1412 (5.61)
Persons encountering health
services for other counseling
and medical advice, not
elsewhere classified (Z71)
No 470703 (98.84) 24641 (97.89)
<0.001
Yes 5526 (1.16) 530 (2.11)
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Long term (current) drug
therapy (Z79)
No 468219 (98.32) 24619 (97.81)
<0.001
Yes 8010 (1.68) 552 (2.19)
Family history of certain
disabilities and chronic
diseases (leading to
disablement) (Z82)
No 467499 (98.17) 24836 (98.67)
<0.001
Yes 8730 (1.83) 335 (1.33)
Family history of other
specific disorders (Z83)
No 470836 (98.87) 24896 (98.91)
0.580
Yes 5393 (1.13) 275 (1.09)
Personal history of certain
other diseases (Z86)
No 470511 (98.80) 24675 (98.03)
<0.001
Yes 5718 (1.20) 496 (1.97)
Personal history of other
diseases and conditions (Z87)
No 466394 (97.93) 24455 (97.16)
<0.001
Yes 9835 (2.07) 716 (2.84)
Personal risk factors, not
elsewhere classified (Z91)
No 464485 (97.53) 24473 (97.23)
0.002
Yes 11744 (2.47) 698 (2.77)
Artificial opening status
(Z93)
No 465233 (97.69) 23840 (94.71)
<0.001
Yes 10996 (2.31) 1331 (5.29)
Other postprocedural states
(Z98)
No 466131 (97.88) 24328 (96.65)
<0.001
Yes 10098 (2.12) 843 (3.35)
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Table 4.3: Results of the multivariate statistical analysis
Variable Levels Odds ratio p value
Sex
Female Reference < 0.001
Male 0.943 (0.914,
0.973)
Payer
Commercial Reference
< 0.001
Governmental
(Medicare,
Medicaid)
1.347 (1.293,
1.404)
Other Governmental
(Champus, etc)
1.212 (1.114,
1.319)
Self-pay 1.296 (1.157,
1.452)
Other 1.343 (1.275,
1.413)
Race/Ethnicity
Caucasian Reference
Hispanic 1.106 (1.014,
1.207)
0.023
Black/African
American
1.140 (1.091,
1.191)
< 0.001
Asian/Pacific
Islander
1.004 (0.893,
1.129)
0.947
Native American 1.145 (0.995,
1.317)
0.059
Other/Unknown 1.112 (1.061,
1.166)
< 0.001
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Previous ED visits (last 6mo) - 0.621 (0.595, 0.649) < 0.001
Maximum previous length of stay (last
6mo)
- 1.042 (1.040, 1.044) < 0.001
Free-standing pediatric hospital Yes 1.431 (0.659, 3.107) 0.364
EmergentAdmission Yes 1.672 (1.598, 1.749) < 0.001
ReadmissionHistory Yes 1.179 (1.124, 1.236) < 0.001
Other sepsis (A41) Yes 1.599 (1.449, 1.764) < 0.001
Other bacterial agents as the cause of
diseases classified elsewhere (B96)
Yes 1.912 (1.740, 2.100) < 0.001
Lymphoid leukemia (C91) Yes 0.562 (0.494, 0.640) < 0.001
Type 1 diabetes mellitus (E10) Yes 0.279 (0.211, 0.369) < 0.001
Cerebral palsy (G80) Yes 1.314 (1.156, 1.494) < 0.001
Other disorders of brain (G93) Yes 1.224 (1.119, 1.340) < 0.001
Suppurative and unspecified otitis me-
dia (H66)
Yes 0.522 (0.422, 0.645) < 0.001
Bacterial pneumonia, not elsewhere
classified (J15)
Yes 1.867 (1.664, 2.094) < 0.001
Pneumonia, unspecified organism
(J18)
Yes 0.796 (0.727, 0.872) < 0.001
Disorders of newborn related to short
gestation and low birth weight, not
elsewhere classified (P07)
Yes 5.466 (5.084, 5.877) < 0.001
Respiratory distress of newborn (P22) Yes 1.839 (1.687, 2.004) < 0.001
Other respiratory conditions originat-
ing in the perinatal period (P28)
Yes 2.579 (2.368, 2.810) < 0.001
Cardiovascular disorders originating in
the perinatal period (P29)
Yes 1.184 (1.071, 1.309) < 0.001
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Other conditions originating in the
perinatal period (P96)
Yes 2.412 (2.180, 2.668) < 0.001
Abnormalities of heart beat (R00) Yes 1.106 (1.024, 1.195) 0.010
Symptoms and signs concerning food
and fluid intake (R63)
Yes 1.630 (1.525, 1.742) < 0.001
Surgical operation and other surgical
procedures as the cause of abnormal re-
action of the patient, or of later compli-
cation, without mention of misadven-
ture at the time of the procedure (Y83)
Yes 1.227 (1.091, 1.380) < 0.001
Encounter for observation and evalua-
tion of newborn for suspected diseases
and conditions ruled out (Z05)
Yes 1.239 (1.126, 1.363) < 0.001
Encounter for immunization (Z23) Yes 1.133 (1.029, 1.248) 0.011
Family history of certain disabilities
and chronic diseases (leading to dis-
ablement) (Z82)
Yes 0.641 (0.551, 0.745) < 0.001
Personal history of other diseases and
conditions (Z87)
Yes 0.816 (0.734, 0.907) < 0.001
Other postprocedural states (Z98) Yes 0.698 (0.632, 0.770) < 0.001
Pervasive developmental disorders
(F84)
Yes 0.577 (0.373, 0.893) 0.013
Sleep disorders (G47) Yes 0.989 (0.842, 1.162) 0.891
Other functional intestinal disorders
(K59)
Yes 1.028 (0.895, 1.181) 0.699
Reaction to severe stress, and adjust-
ment disorders (F43)
Yes 1.354 (1.157, 1.585) < 0.001
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Streptococcus, Staphylococcus, and
Enterococcus as the cause of diseases
classified elsewhere (B95)
Yes 1.031 (1.017, 1.046) < 0.001
Other anemias (D64) Yes 0.965 (0.953, 0.978) < 0.001
Major depressive disorder, single
episode (F32)
Yes 0.946 (0.918, 0.976) < 0.001
Pervasive developmental disorders
(F84)
Yes 1.063 (1.026, 1.102) < 0.001
Attention-deficit hyperactivity disor-
ders (F90)
Yes 0.934 (0.909, 0.960) < 0.001
Sleep disorders (G47) Yes 1.031 (1.014, 1.047) < 0.001
Asthma (J45) Yes 1.052 (1.036, 1.068) < 0.001
Other functional intestinal disorders
(K59)
Yes 1.032 (1.020, 1.044) < 0.001
Obstructive and reflux uropathy (N13) Yes 0.947 (0.921, 0.974) < 0.001
Other disorders of urinary system
(N39)
Yes 1.034 (1.016, 1.052) < 0.001
Convulsions, not elsewhere classified
(R56)
Yes 0.956 (0.936, 0.977) < 0.001
Outcome of delivery (Z37) Yes 0.904 (0.873, 0.935) < 0.001
Viral and other specified intestinal in-
fections (A08)
Present 1.096 (1.064, 1.128) < 0.001
Viral agents as the cause of diseases
classified elsewhere (B97)
Present 1.044 (1.031, 1.058) < 0.001
Sickle-cell disorders (D57) Present 1.042 (1.023, 1.062) < 0.001
Neutropenia (D70) Present 1.035 (1.023, 1.047) < 0.001
Volume depletion (E86) Present 1.048 (1.038, 1.058) < 0.001
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Other disorders of fluid, electrolyte and
acid-base balance (E87)
Present 0.980 (0.975, 0.986) < 0.001
Reaction to severe stress, and adjust-
ment disorders (F43)
Present 1.032 (1.018, 1.047) < 0.001
Conduct disorders (F91) Present 1.066 (1.044, 1.089) < 0.001
Epilepsy and recurrent seizures (G40) Present 1.026 (1.017, 1.035) < 0.001
Essential (primary) hypertension (I10) Present 0.969 (0.959, 0.978) < 0.001
Acute upper respiratory infections of
multiple and unspecified sites (J06)
Present 1.047 (1.029, 1.065) < 0.001
Acute bronchiolitis (J21) Present 1.086 (1.071, 1.101) < 0.001
Asthma (J45) Present 1.026 (1.017, 1.034) < 0.001
Respiratory failure, not elsewhere clas-
sified (J96)
Present 0.977 (0.970, 0.983) < 0.001
Other respiratory disorders (J98) Present 0.986 (0.979, 0.994) < 0.001
Gastro-esophageal reflux disease (K21) Present 1.025 (1.016, 1.033) < 0.001
Acute appendicitis (K35) Present 1.076 (1.052, 1.100) < 0.001
Other functional intestinal disorders
(K59)
Present 0.987 (0.980, 0.994) < 0.001
Cellulitis and acute lymphangitis (L03) Present 1.065 (1.050, 1.080) < 0.001
Scoliosis (M41) Present 0.964 (0.951, 0.976) < 0.001
Disorders of newborn related to long
gestation and high birth weight (P08)
Present 1.124 (1.080, 1.169) < 0.001
Neonatal jaundice from other and un-
specified causes (P59)
Present 1.049 (1.035, 1.063) < 0.001
Transitory disorders of carbohydrate
metabolism specific to newborn (P70)
Present 1.044 (1.022, 1.067) < 0.001
Feeding problems of newborn (P92) Present 1.076 (1.059, 1.093) < 0.001
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Congenital malformations of cardiac
septa (Q21)
Present 0.955 (0.949, 0.962) < 0.001
Congenital malformations of great ar-
teries (Q25)
Present 0.965 (0.957, 0.974) < 0.001
Abnormalities of breathing (R06) Present 1.043 (1.036, 1.051) < 0.001
Other symptoms and signs involving
the circulatory and respiratory system
(R09)
Present 1.022 (1.013, 1.032) < 0.001
Abdominal and pelvic pain (R10) Present 1.035 (1.023, 1.047) < 0.001
Nausea and vomiting (R11) Present 1.028 (1.019, 1.036) < 0.001
Symptoms and signs involving emo-
tional state (R45)
Present 1.052 (1.035, 1.069) < 0.001
Fever of other and unknown origin
(R50)
Present 1.036 (1.028, 1.043) < 0.001
Convulsions, not elsewhere classified
(R56)
Present 1.053 (1.041, 1.065) < 0.001
Lack of expected normal physiological
development in childhood and adults
(R62)
Present 1.023 (1.015, 1.032) < 0.001
Place of occurrence of the external
cause (Y92)
Present 1.034 (1.023, 1.044) < 0.001
Outcome of delivery (Z37) Present 1.047 (1.019, 1.076) < 0.001
Liveborn infants according to place of
birth and type of delivery (Z38)
Present 1.369 (1.342, 1.395) < 0.001
Encounter for other aftercare and med-
ical care (Z51)
Present 1.048 (1.039, 1.057) < 0.001
97
Personal risk factors, not elsewhere
classified (Z91)
Present 1.024 (1.012, 1.036) < 0.001
Artificial opening status (Z93) Present 1.024 (1.014, 1.033) < 0.001
Table 4.5: Summary Statistics LOS Pediatrics
Variables Levels
LOS 1 week
or less
LOS > 1
week
p value
(chi-
squared
or t-test)
n (%) or
mean (sd)
n (%) or
mean (sd)
Sex
Female 225492
(47.35)
11553 (45.90)
< 0.001
Male 250737
(52.65)
13618 (54.10)
Payer
Commercial 152772
(32.08)
6917 (27.48)
< 0.001Governmental
(Medicare,
Medicaid)
184555
(38.75)
11777 (46.79)
Other
Governmental
(Champus, etc)
18226 (3.83) 1001 (3.98)
Self-pay 10674 (2.24) 460 (1.83)
Other 110002
(23.10)
5016 (19.93)
Age AGE 5.93 (6.08) 4.56 (5.97) < 0.001
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Race/Ethnicity
Caucasian 255472
(53.64)
12860 (51.09)
< 0.001
Hispanic 17889 (3.76) 895 (3.56)
Black/African
American
106198
(22.30)
5489 (21.81)
Asian/Pacific
Islander
8702 (1.83) 427 (1.70)
Native American 6920 (1.45) 425 (1.69)
Other/Unknown 81048 (17.02) 5075 (20.16)
Previous ED visits (last
6mo)
prevEDcat0 363531
(76.34)
21140 (83.99)
< 0.001
prevEDcat1 112698
(23.66)
4031 (16.01)
Maximum previous
length of stay (last 6mo)
- 1.52 (4.95) 4.33 (9.59) < 0.001
Number of medications Number Of Meds 2.23 (4.45) 11.16 (11.41) < 0.001
Number of procedures Number Of
Procedure
0.10 (0.51) 0.32 (1.01)
Emergent Admission
No 77436 (16.26) 3772 (14.99)
< 0.001
Yes 398793
(83.74)
21399 (85.01)
Readmission History
No 415569
(87.26)
19766 (78.53)
< 0.001
Yes 60660 (12.74) 5405 (21.47)
Free. . .
is Pediatric 0 236191
(49.60)
10269 (40.80)
< 0.001
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is Pediatric 1 240038
(50.40)
14902 (59.20)
Viral and other specified
intestinal infections (A08)
No 471186
(98.94)
25024 (99.42)
< 0.001
Yes 5043 (1.06) 147 (0.58)
Other sepsis (A41)
No 471695
(99.05)
24017 (95.42)
< 0.001
Yes 4534 (0.95) 1154 (4.58)
Viral infection of
unspecified site (B34)
No 470270
(98.75)
24789 (98.48)
< 0.001
Yes 5959 (1.25) 382 (1.52)
Streptococcus,
Staphylococcus, and
Enterococcus as the cause of
diseases classified elsewhere
(B95)
No 468183
(98.31)
23936 (95.09)
< 0.001
Yes 8046 (1.69) 1235 (4.91)
Other bacterial agents as the
cause of diseases classified
elsewhere (B96)
No 469698
(98.63)
23888 (94.90)
< 0.001
Yes 6531 (1.37) 1283 (5.10)
Viral agents as the cause of
diseases classified elsewhere
(B97)
No 460317
(96.66)
24431 (97.06)
< 0.001
Yes 15912 (3.34) 740 (2.94)
Lymphoid leukemia (C91)
No 470587
(98.82)
24676 (98.03)
< 0.001
Yes 5642 (1.18) 495 (1.97)
Sickle-cell disorders (D57)
No 467694
(98.21)
24964 (99.18)
< 0.001
100
Yes 8535 (1.79) 207 (0.82)
Other anemias (D64)
No 466525
(97.96)
23589 (93.71)
< 0.001
Yes 9704 (2.04) 1582 (6.29)
Purpura and other
hemorrhagic conditions (D69)
No 471560
(99.02)
24293 (96.51)
< 0.001
Yes 4669 (0.98) 878 (3.49)
Neutropenia (D70)
No 470668
(98.83)
24190 (96.10)
< 0.001
Yes 5561 (1.17) 981 (3.90)
Other disorders of white
blood cells (D72)
No 470868
(98.87)
24638 (97.88)
<0.001
Yes 5361 (1.13) 533 (2.12)
Type 1 diabetes mellitus (E10)
No 469772
(98.64)
25108 (99.75)
<0.001
Yes 6457 (1.36) 63 (0.25)
Overweight and obesity (E66)
No 469530
(98.59)
24848 (98.72)
0.110
Yes 6699 (1.41) 323 (1.28)
Volume depletion (E86)
No 449670
(94.42)
24209 (96.18)
< 0.001
Yes 26559 (5.58) 962 (3.82)
Other disorders of fluid,
electrolyte and acid-base
balance (E87)
No 461167
(96.84)
21606 (85.84)
< 0.001
Yes 15062 (3.16) 3565 (14.16)
Major depressive disorder,
single episode (F32)
No 467416
(98.15)
24435 (97.08)
< 0.001
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Yes 8813 (1.85) 736 (2.92)
Other anxiety disorders (F41)
No 466936
(98.05)
24511 (97.38)
< 0.001
Yes 9293 (1.95) 660 (2.62)
Reaction to severe stress, and
adjustment disorders (F43)
No 469188
(98.52)
24576 (97.64) < 0.001
Yes 7041 (1.48) 595 (2.36)
Pervasive developmental
disorders (F84)
No 471185
(98.94)
24882 (98.85)
0.190
Yes 5044 (1.06) 289 (1.15)
ther disorders of
psychological development
(F88)
No 471193
(98.94)
24736 (98.27)
<0.001
Yes 5036 (1.06) 435 (1.73)
Attention-deficit
hyperactivity disorders (F90)
No 464585
(97.55)
24456 (97.16)
<0.001
Yes 11644 (2.45) 715 (2.84)
Conduct disorders (F91)
No 471128
(98.93)
24527 (97.44)
< 0.001
Yes 5101 (1.07) 644 (2.56)
Epilepsy and recurrent
seizures (G40)
No 458341
(96.24)
24071 (95.63)
< 0.001
Yes 17888 (3.76) 1100 (4.37)
Sleep disorders (G47)
No 467634
(98.20)
24355 (96.76)
< 0.001
Yes 8595 (1.80) 816 (3.24)
Cerebral palsy (G80)
No 469797
(98.65)
24653 (97.94)
< 0.001
102
Yes 6432 (1.35) 518 (2.06)
Other disorders of brain (G93)
No 468274
(98.33)
23958 (95.18)
< 0.001
Yes 7955 (1.67) 1213 (4.82)
Suppurative and unspecified
otitis media (H66)
No 468492
(98.38)
25038 (99.47)
< 0.001
Yes 7737 (1.62) 133 (0.53)
Essential (primary)
hypertension (I10)
No 471850
(99.08)
24404 (96.95)
< 0.001
Yes 4379 (0.92) 767 (3.05)
Other cardiac arrhythmias
(I49)
No 471856
(99.08)
24354 (96.75)
< 0.001
Yes 4373 (0.92) 817 (3.25)
Acute upper respiratory
infections of multiple and
unspecified sites (J06)
No 463782
(97.39)
24827 (98.63)
< 0.001
Yes 12447 (2.61) 344 (1.37)
Bacterial pneumonia, not
elsewhere classified (J15)
No 470220
(98.74)
24465 (97.20)
< 0.001
Yes 6009 (1.26) 706 (2.80)
Pneumonia, unspecified
organism (J18)
No 459014
(96.39)
24188 (96.09)
0.017
Yes 17215 (3.61) 983 (3.91)
Acute bronchiolitis (J21)
No 455023
(95.55)
24546 (97.52)
<0.001
Yes 21206 (4.45) 625 (2.48)
Asthma (J45)
No 432614
(90.84)
24200 (96.14)
<0.001
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Yes 43615 (9.16) 971 (3.86)
Acute respiratory distress
syndrome (J80)
No 470722
(98.84)
24815 (98.59)
<0.001
Yes 5507 (1.16) 356 (1.41)
Respiratory failure, not
elsewhere classified (J96)
No 467134
(98.09)
22885 (90.92)
< 0.001
Yes 9095 (1.91) 2286 (9.08)
Other respiratory disorders
(J98)
No 465501
(97.75)
23391 (92.93)
< 0.001
Yes 10728 (2.25) 1780 (7.07)
Gastro-esophageal reflux
disease K21
No 460106
(96.61)
23263 (92.42)
< 0.001
Yes 16123 (3.39) 1908 (7.58)
Acute appendicitis (K35)
No 468467
(98.37)
25016 (99.38)
< 0.001
Yes 7762 (1.63) 155 (0.62)
Other and unspecified
noninfective gastroenteritis
and colitis (K52)
No 466229
(97.90)
24407 (96.96)
< 0.001
Yes 10000 (2.10) 764 (3.04)
Paralytic ileus and intestinal
obstruction without hernia
(K56)
No 471611
(99.03)
24491 (97.30)
<0.001
Yes 4618 (0.97) 680 (2.70)
Other functional intestinal
disorders (K59)
No 457981
(96.17)
23391 (92.93)
<0.001
Yes 18248 (3.83) 1780 (7.07)
Cellulitis and acute
lymphangitis (L03)
No 465002
(97.64)
24720 (98.21)
<0.001
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Yes 11227 (2.36) 451 (1.79)
Scoliosis (M41)
No 471283
(98.96)
24868 (98.80)
0.013
Yes 4946 (1.04) 303 (1.20)
Other and unspecified soft
tissue disorders, not
elsewhere classified (M79)
No 471580
(99.02)
24875 (98.82)
0.002
Yes 4649 (0.98) 296 (1.18)
Obstructive and reflux
uropathy (N13)
No 470817
(98.86)
24689 (98.09)
< 0.001
Yes 5412 (1.14) 482 (1.91)
Other disorders of urinary
system (N39)
No 468334
(98.34)
24484 (97.27)
< 0.001
Yes 7895 (1.66) 687 (2.73)
Disorders of newborn related
to short gestation and low
birth weight, not elsewhere
classified (P07)
No 469040
(98.49)
20310 (80.69)
< 0.001
Yes 7189 (1.51) 4861 (19.31)
Disorders of newborn related
to long gestation and high
birth weight (P08)
No 469849
(98.66)
24934 (99.06)
< 0.001
Yes 6380 (1.34) 237 (0.94)
Respiratory distress of
newborn (P22)
No 471406
(98.99)
22051 (87.60)
< 0.001
Yes 4823 (1.01) 3120 (12.40)
Other respiratory conditions
originating in the perinatal
period (P28)
No 470980
(98.90)
21584 (85.75)
< 0.001
Yes 5249 (1.10) 3587 (14.25)
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Cardiovascular disorders
originating in the perinatal
period (P29)
No 471319
(98.97)
22500 (89.39)
< 0.001
Yes 4910 (1.03) 2671 (10.61)
Neonatal jaundice from other
and unspecified causes (P59)
No 460905
(96.78)
21370 (84.90)
< 0.001
Yes 15324 (3.22) 3801 (15.10)
Transitory disorders of
carbohydrate metabolism
specific to newborn (P70)
No 472203
(99.15)
23975 (95.25)
< 0.001
Yes 4026 (0.85) 1196 (4.75)
Feeding problems of newborn
(P92)
No 471859
(99.08)
22596 (89.77)
< 0.001
Yes 4370 (0.92) 2575 (10.23)
Other conditions originating
in the perinatal period (P96)
No 470078
(98.71)
23245 (92.35)
< 0.001
Yes 6151 (1.29) 1926 (7.65)
Congenital malformations of
cardiac septa (Q21)
No 467151
(98.09)
22430 (89.11)
< 0.001
Yes 9078 (1.91) 2741 (10.89)
Congenital malformations of
great arteries (Q25)
No 472180
(99.15)
23090 (91.73)
< 0.001
Yes 4049 (0.85) 2081 (8.27)
Abnormalities of heart beat (R00)
No 462313
(97.08)
23585 (93.70)
< 0.001
Yes 13916 (2.92) 1586 (6.30)
Cough (R05)
No 469262
(98.54)
24923 (99.01)
< 0.001
Yes 6967 (1.46) 248 (0.99)
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Abnormalities of breathing (R06)
No 446092
(93.67)
22427 (89.10)
<0.001
Yes 30137 (6.33) 2744 (10.90)
Other symptoms and signs
involving the circulatory and
respiratory system (R09)
No 454487
(95.43)
24095 (95.73) 0.032
Yes 21742 (4.57) 1076 (4.27)
Abdominal and pelvic pain (R10)
No 460785
(96.76)
24550 (97.53)
<0.001
Yes 15444 (3.24) 621 (2.47)
Nausea and vomiting (R11)
No 454020
(95.34)
23773 (94.45)
<0.001
Yes 22209 (4.66) 1398 (5.55)
Other symptoms and signs
involving the digestive
system and abdomen (R19)
No 467938
(98.26)
24396 (96.92)
<0.001
Yes 8291 (1.74) 775 (3.08)
Symptoms and signs
involving emotional state
(R45)
No 468191
(98.31)
24591 (97.70)
<0.001
Yes 8038 (1.69) 580 (2.30)
Fever of other and unknown
origin (R50)
No 442745
(92.97)
23372 (92.85)
0.491
Yes 33484 (7.03) 1799 (7.15)
Headache (R51)
No 470066
(98.71)
24819 (98.60)
0.163
Yes 6163 (1.29) 352 (1.40)
Convulsions, not elsewhere
classified (R56)
No 462717
(97.16)
24526 (97.44)
0.011
Yes 13512 (2.84) 645 (2.56)
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Lack of expected normal
physiological development in
childhood and adults (R62)
No 462776
(97.18)
23701 (94.16)
< 0.001
Yes 13453 (2.82) 1470 (5.84)
Symptoms and signs
concerning food and fluid
intake (R63)
No 462577
(97.13)
22677 (90.09)
< 0.001
Yes 13652 (2.87) 2494 (9.91)
Findings of drugs and other
substances, not normally
found in blood (R78)
No 471642
(99.04)
24431 (97.06)
< 0.001
Yes 4587 (0.96) 740 (2.94)
Surgical operation and other
surgical procedures as the
cause of abnormal reaction of
the patient, or of later
complication, without
mention of misadventure at
the time of the procedure
(Y83)
No 471665
(99.04)
24491 (97.30)
< 0.001
Yes 4564 (0.96) 680 (2.70)
Place of occurrence of the
external cause (Y92)
No 463240
(97.27)
24308 (96.57)
< 0.001
Yes 12989 (2.73) 863 (3.43)
Encounter for observation
and evaluation of newborn
for suspected diseases and
conditions ruled out (Z05)
No 469243
(98.53)
23633 (93.89)
<0.001
Yes 6986 (1.47) 1538 (6.11)
Encounter for immunization
(Z23)
No 459579
(96.50)
23633 (93.89)
<0.001
Yes 16650 (3.50) 1538 (6.11)
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Outcome of delivery (Z37)
No 468046
(98.28)
25032 (99.45)
<0.001
Yes 8183 (1.72) 139 (0.55)
Liveborn infants according to
place of birth and type of
delivery (Z38)
No 418130
(87.80)
22153 (88.01)
0.326
Yes 58099 (12.20) 3018 (11.99)
Encounter for other aftercare
and medical care (Z51)
No 462358
(97.09)
23759 (94.39)
<0.001
Yes 13871 (2.91) 1412 (5.61)
Persons encountering health
services for other counseling
and medical advice, not
elsewhere classified (Z71)
No 470703
(98.84)
24641 (97.89)
<0.001
Yes 5526 (1.16) 530 (2.11)
Long term (current) drug
therapy (Z79)
No 468219
(98.32)
24619 (97.81)
<0.001
Yes 8010 (1.68) 552 (2.19)
Family history of certain
disabilities and chronic
diseases (leading to
disablement) (Z82)
No 467499
(98.17)
24836 (98.67)
<0.001
Yes 8730 (1.83) 335 (1.33)
Family history of other
specific disorders (Z83)
No 470836
(98.87)
24896 (98.91)
0.580
Yes 5393 (1.13) 275 (1.09)
Personal history of certain
other diseases (Z86)
No 470511
(98.80)
24675 (98.03)
<0.001
Yes 5718 (1.20) 496 (1.97)
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Personal history of other
diseases and conditions (Z87)
No 466394
(97.93)
24455 (97.16)
<0.001
Yes 9835 (2.07) 716 (2.84)
Personal risk factors, not
elsewhere classified (Z91)
No 464485
(97.53)
24473 (97.23)
0.002
Yes 11744 (2.47) 698 (2.77)
Artificial opening status
(Z93)
No 465233
(97.69)
23840 (94.71)
<0.001
Yes 10996 (2.31) 1331 (5.29)
Other postprocedural
states (Z98)
No 466131
(97.88)
24328 (96.65)
<0.001
Yes 10098 (2.12) 843 (3.35)
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Table 4.6: Results of the multivariate statistical analysis
Variable Levels Odds ratio p value
Sex
Female Reference < 0.001
Male 0.943 (0.914,
0.973)
Payer
Commercial Reference
< 0.001
Governmental
(Medicare,
Medicaid)
1.347 (1.293,
1.404)
Other Governmental
(Champus, etc)
1.212 (1.114,
1.319)
Self-pay 1.296 (1.157,
1.452)
Other 1.343 (1.275,
1.413)
Race/Ethnicity
Caucasian Reference
Hispanic 1.106 (1.014,
1.207)
0.023
Black/African
American
1.140 (1.091,
1.191)
< 0.001
Asian/Pacific
Islander
1.004 (0.893,
1.129)
0.947
Native American 1.145 (0.995,
1.317)
0.059
Other/Unknown 1.112 (1.061,
1.166)
< 0.001
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Previous ED visits (last 6mo) - 0.621 (0.595,
0.649)
< 0.001
Maximum previous length of stay
(last 6mo)
- 1.042 (1.040,
1.044)
< 0.001
Free-standing pediatric hospital Yes 1.431 (0.659,
3.107)
0.364
EmergentAdmission Yes 1.672 (1.598,
1.749)
< 0.001
ReadmissionHistory Yes 1.179 (1.124,
1.236)
< 0.001
Other sepsis (A41) Yes 1.599 (1.449,
1.764)
< 0.001
Other bacterial agents as the
cause of diseases classified else-
where (B96)
Yes 1.912 (1.740,
2.100)
< 0.001
Lymphoid leukemia (C91) Yes 0.562 (0.494,
0.640)
< 0.001
Type 1 diabetes mellitus (E10) Yes 0.279 (0.211,
0.369)
< 0.001
Cerebral palsy (G80) Yes 1.314 (1.156,
1.494)
< 0.001
Other disorders of brain (G93) Yes 1.224 (1.119,
1.340)
< 0.001
Suppurative and unspecified oti-
tis media (H66)
Yes 0.522 (0.422,
0.645)
< 0.001
Bacterial pneumonia, not else-
where classified (J15)
Yes 1.867 (1.664,
2.094)
< 0.001
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Pneumonia, unspecified organ-
ism (J18)
Yes 0.796 (0.727,
0.872)
< 0.001
Disorders of newborn related to
short gestation and low birth
weight, not elsewhere classified
(P07)
Yes 5.466 (5.084,
5.877)
< 0.001
Respiratory distress of newborn
(P22)
Yes 1.839 (1.687,
2.004)
< 0.001
Other respiratory conditions
originating in the perinatal
period (P28)
Yes 2.579 (2.368,
2.810)
< 0.001
Cardiovascular disorders origi-
nating in the perinatal period
(P29)
Yes 1.184 (1.071,
1.309)
< 0.001
Other conditions originating in
the perinatal period (P96)
Yes 2.412 (2.180,
2.668)
< 0.001
Abnormalities of heart beat
(R00)
Yes 1.106 (1.024,
1.195)
0.010
Symptoms and signs concerning
food and fluid intake (R63)
Yes 1.630 (1.525,
1.742)
< 0.001
Surgical operation and other sur-
gical procedures as the cause of
abnormal reaction of the patient,
or of later complication, without
mention of misadventure at the
time of the procedure (Y83)
Yes 1.227 (1.091,
1.380)
< 0.001
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Encounter for observation and
evaluation of newborn for sus-
pected diseases and conditions
ruled out (Z05)
Yes 1.239 (1.126,
1.363)
< 0.001
Encounter for immunization
(Z23)
Yes 1.133 (1.029,
1.248)
0.011
Family history of certain disabili-
ties and chronic diseases (leading
to disablement) (Z82)
Yes 0.641 (0.551,
0.745)
< 0.001
Personal history of other diseases
and conditions (Z87)
Yes 0.816 (0.734,
0.907)
< 0.001
Other postprocedural states
(Z98)
Yes 0.698 (0.632,
0.770)
< 0.001
Pervasive developmental disor-
ders (F84)
Yes 0.577 (0.373,
0.893)
0.013
Sleep disorders (G47) Yes 0.989 (0.842,
1.162)
0.891
Other functional intestinal disor-
ders (K59)
Yes 1.028 (0.895,
1.181)
0.699
Reaction to severe stress, and ad-
justment disorders (F43)
Yes 1.354 (1.157,
1.585)
< 0.001
Streptococcus, Staphylococcus,
and Enterococcus as the cause
of diseases classified elsewhere
(B95)
Yes 1.031 (1.017,
1.046)
< 0.001
Other anemias (D64) Yes 0.965 (0.953,
0.978)
< 0.001
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Major depressive disorder, single
episode (F32)
Yes 0.946 (0.918,
0.976)
< 0.001
Pervasive developmental disor-
ders (F84)
Yes 1.063 (1.026,
1.102)
< 0.001
Attention-deficit hyperactivity
disorders (F90)
Yes 0.934 (0.909,
0.960)
< 0.001
Sleep disorders (G47) Yes 1.031 (1.014,
1.047)
< 0.001
Asthma (J45) Yes 1.052 (1.036,
1.068)
< 0.001
Other functional intestinal disor-
ders (K59)
Yes 1.032 (1.020,
1.044)
< 0.001
Obstructive and reflux uropathy
(N13)
Yes 0.947 (0.921,
0.974)
< 0.001
Other disorders of urinary sys-
tem (N39)
Yes 1.034 (1.016,
1.052)
< 0.001
Convulsions, not elsewhere clas-
sified (R56)
Yes 0.956 (0.936,
0.977)
< 0.001
Outcome of delivery (Z37) Yes 0.904 (0.873,
0.935)
< 0.001
Viral and other specified intesti-
nal infections (A08)
Present 1.096 (1.064,
1.128)
< 0.001
Viral agents as the cause of dis-
eases classified elsewhere (B97)
Present 1.044 (1.031,
1.058)
< 0.001
Sickle-cell disorders (D57) Present 1.042 (1.023,
1.062)
< 0.001
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Neutropenia (D70) Present 1.035 (1.023,
1.047)
< 0.001
Volume depletion (E86) Present 1.048 (1.038,
1.058)
< 0.001
Other disorders of fluid, elec-
trolyte and acid-base balance
(E87)
Present 0.980 (0.975,
0.986)
< 0.001
Reaction to severe stress, and ad-
justment disorders (F43)
Present 1.032 (1.018,
1.047)
< 0.001
Conduct disorders (F91) Present 1.066 (1.044,
1.089)
< 0.001
Epilepsy and recurrent seizures
(G40)
Present 1.026 (1.017,
1.035)
< 0.001
Essential (primary) hypertension
(I10)
Present 0.969 (0.959,
0.978)
< 0.001
Acute upper respiratory infec-
tions of multiple and unspecified
sites (J06)
Present 1.047 (1.029,
1.065)
< 0.001
Acute bronchiolitis (J21) Present 1.086 (1.071,
1.101)
< 0.001
Asthma (J45) Present 1.026 (1.017,
1.034)
< 0.001
Respiratory failure, not else-
where classified (J96)
Present 0.977 (0.970,
0.983)
< 0.001
Other respiratory disorders (J98) Present 0.986 (0.979,
0.994)
< 0.001
116
Gastro-esophageal reflux disease
(K21)
Present 1.025 (1.016,
1.033)
< 0.001
Acute appendicitis (K35) Present 1.076 (1.052,
1.100)
< 0.001
Other functional intestinal disor-
ders (K59)
Present 0.987 (0.980,
0.994)
< 0.001
Cellulitis and acute lymphangitis
(L03)
Present 1.065 (1.050,
1.080)
< 0.001
Scoliosis (M41) Present 0.964 (0.951,
0.976)
< 0.001
Disorders of newborn related to
long gestation and high birth
weight (P08)
Present 1.124 (1.080,
1.169)
< 0.001
Neonatal jaundice from other
and unspecified causes (P59)
Present 1.049 (1.035,
1.063)
< 0.001
Transitory disorders of carbo-
hydrate metabolism specific to
newborn (P70)
Present 1.044 (1.022,
1.067)
< 0.001
Feeding problems of newborn
(P92)
Present 1.076 (1.059,
1.093)
< 0.001
Congenital malformations of car-
diac septa (Q21)
Present 0.955 (0.949,
0.962)
< 0.001
Congenital malformations of
great arteries (Q25)
Present 0.965 (0.957,
0.974)
< 0.001
Abnormalities of breathing
(R06)
Present 1.043 (1.036,
1.051)
< 0.001
117
Other symptoms and signs in-
volving the circulatory and res-
piratory system (R09)
Present 1.022 (1.013,
1.032)
< 0.001
Abdominal and pelvic pain
(R10)
Present 1.035 (1.023,
1.047)
< 0.001
Nausea and vomiting (R11) Present 1.028 (1.019,
1.036)
< 0.001
Symptoms and signs involving
emotional state (R45)
Present 1.052 (1.035,
1.069)
< 0.001
Fever of other and unknown ori-
gin (R50)
Present 1.036 (1.028,
1.043)
< 0.001
Convulsions, not elsewhere clas-
sified (R56)
Present 1.053 (1.041,
1.065)
< 0.001
Lack of expected normal physio-
logical development in childhood
and adults (R62)
Present 1.023 (1.015,
1.032)
< 0.001
Place of occurrence of the exter-
nal cause (Y92)
Present 1.034 (1.023,
1.044)
< 0.001
Outcome of delivery (Z37) Present 1.047 (1.019,
1.076)
< 0.001
Liveborn infants according to
place of birth and type of deliv-
ery (Z38)
Present 1.369 (1.342,
1.395)
< 0.001
Encounter for other aftercare and
medical care (Z51)
Present 1.048 (1.039,
1.057)
< 0.001
Personal risk factors, not else-
where classified (Z91)
Present 1.024 (1.012,
1.036)
< 0.001
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Artificial opening status (Z93) Present 1.024 (1.014,
1.033)
< 0.001
Table 4.8: Statistical interactions with age
Variable
Regression
coefficient
p value
Main effects of the interactions
Age -0.042
< 0.001
Streptococcus, Staphylococcus, and
Enterococcus as the cause of diseases classified
elsewhere (B95)
0.342
Other anemias (D64) 0.371
Major depressive disorder, single episode (F32) 1.418
Pervasive developmental disorders (F84) -0.549
Attention-deficit hyperactivity disorders (F90) 1.035
Sleep disorders (G47) -0.011
Asthma (J45) -1.437
Other functional intestinal disorders (K59) 0.027
Obstructive and reflux uropathy (N13) -0.282
Other disorders of urinary system (N39) -0.291
Convulsions, not elsewhere classified (R56) -0.714
Outcome of delivery (Z37) -0.528
Interaction terms with age
Streptococcus, Staphylococcus, and
Enterococcus as the cause of diseases classified
elsewhere (B95)
0.031
< 0.001
Other anemias (D64) -0.035
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Major depressive disorder, single episode (F32) -0.055
Pervasive developmental disorders (F84) 0.061
Attention-deficit hyperactivity disorders (F90) -0.068
Sleep disorders (G47) 0.030
Asthma (J45) 0.051
Other functional intestinal disorders (K59) 0.031
Obstructive and reflux uropathy (N13) -0.054
Other disorders of urinary system (N39) 0.033
Convulsions, not elsewhere classified (R56) -0.045
Outcome of delivery (Z37) -0.101
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Table 4.9: Statistical interactions with the number of medi-
cations
Variable
Regression
coefficient
p value
Main effects of the interactions
Number of medications 0.117
< 0.001
Viral and other specified intestinal infections
(A08)
-1.117
Viral agents as the cause of diseases classified
elsewhere (B97)
-0.549
Sickle-cell disorders (D57) -1.054
Neutropenia (D70) 0.199
Volume depletion (E86) -0.964
Other disorders of fluid, electrolyte and
acid-base balance (E87)
0.592
Reaction to severe stress, and adjustment
disorders (F43)
0.303
Conduct disorders (F91) 0.888
Epilepsy and recurrent seizures (G40) -0.555
Essential (primary) hypertension (I10) 0.417
Acute upper respiratory infections of multiple
and unspecified sites (J06)
-0.797
Acute bronchiolitis (J21) -1.273
Asthma (J45) -1.437
Respiratory failure, not elsewhere classified
(J96)
0.735
Other respiratory disorders (J98) 0.348
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Gastro-esophageal reflux disease (K21) -0.157 0.005
Acute appendicitis (K35) -1.611 < 0.001
Other functional intestinal disorders (K59) 0.027 0.699
Cellulitis and acute lymphangitis (L03) -1.295 < 0.001
Scoliosis (M41) -0.034 0.787
Disorders of newborn related to long gestation
and high birth weight (P08)
-1.213 < 0.001
Neonatal jaundice from other and unspecified
causes (P59)
-0.039 0.421
Transitory disorders of carbohydrate
metabolism specific to newborn (P70)
-0.187 0.017
Feeding problems of newborn (P92) 0.422
< 0.001
Congenital malformations of cardiac septa
(Q21)
0.405
Congenital malformations of great arteries
(Q25)
0.57
Abnormalities of breathing (R06) -0.676
Other symptoms and signs involving the
circulatory and respiratory system (R09)
-0.322
Abdominal and pelvic pain (R10) -0.903
Nausea and vomiting (R11) -0.519
Symptoms and signs involving emotional state
(R45)
-0.387
Fever of other and unknown origin (R50) -0.773
Convulsions, not elsewhere classified (R56) -0.714
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Lack of expected normal physiological
development in childhood and adults (R62)
-0.124 0.037
Place of occurrence of the external cause (Y92) -0.764
< 0.001
Outcome of delivery (Z37) -0.528
Liveborn infants according to place of birth
and type of delivery (Z38)
-1.577
Encounter for other aftercare and medical care
(Z51)
-0.31
Personal risk factors, not elsewhere classified
(Z91)
-0.242 0.002
Artificial opening status (Z93) -0.241 < 0.001
Interaction terms with Number of medications
Viral and other specified intestinal infections
(A08)
0.091
< 0.001
Viral agents as the cause of diseases classified
elsewhere (B97)
0.043
Sickle-cell disorders (D57) 0.041
Neutropenia (D70) 0.034
Volume depletion (E86) 0.047
Other disorders of fluid, electrolyte and
acid-base balance (E87)
-0.02
Reaction to severe stress, and adjustment
disorders (F43)
0.032
Conduct disorders (F91) 0.064
Epilepsy and recurrent seizures (G40) 0.026
Essential (primary) hypertension (I10) -0.032
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Acute upper respiratory infections of multiple
and unspecified sites (J06)
0.046
Acute bronchiolitis (J21) 0.082
Asthma (J45) 0.025
Respiratory failure, not elsewhere classified
(J96)
-0.024
Other respiratory disorders (J98) -0.014
Gastro-esophageal reflux disease (K21) 0.024
Acute appendicitis (K35) 0.073
Other functional intestinal disorders (K59) -0.013
Cellulitis and acute lymphangitis (L03) 0.063
Scoliosis (M41) -0.037
Disorders of newborn related to long gestation
and high birth weight (P08)
0.117
Neonatal jaundice from other and unspecified
causes (P59)
0.048
Transitory disorders of carbohydrate
metabolism specific to newborn (P70)
0.043
Feeding problems of newborn (P92) 0.073
Congenital malformations of cardiac septa
(Q21)
-0.046
Congenital malformations of great arteries
(Q25)
-0.036
Abnormalities of breathing (R06) 0.042
Other symptoms and signs involving the
circulatory and respiratory system (R09)
0.022
Abdominal and pelvic pain (R10) 0.034
Nausea and vomiting (R11) 0.027
124
Symptoms and signs involving emotional state
(R45)
0.051
Fever of other and unknown origin (R50) 0.035
Convulsions, not elsewhere classified (R56) 0.052
Lack of expected normal physiological
development in childhood and adults (R62)
0.023
Place of occurrence of the external cause (Y92) 0.033
Outcome of delivery (Z37) 0.046
Liveborn infants according to place of birth
and type of delivery (Z38)
0.314
Encounter for other aftercare and medical care
(Z51)
0.047
Personal risk factors, not elsewhere classified
(Z91)
0.023
Artificial opening status (Z93) 0.023
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[12] J.-W. Lin and A. I. McLeod, Improved peňa–rodriguez portmanteau test, Computational
Statistics & Data Analysis 51, 1731–1738 (2006).
[13] S. K. Safi and A. A. Al-Reqep, Comparative study of portmanteau tests for the residuals
autocorrelation in arma models, Comparative study of portmanteau tests for the residuals
autocorrelation in ARMA models 2 (2014).
[14] G. Barnard, A new test for 2× 2 tables, Nature 156, 177 (1945).
[15] R. A. Fisher, On the interpretation of χ 2 from contingency tables, and the calculation of p,
Journal of the Royal Statistical Society 85, 87–94 (1922).
[16] R. Boschloo, Raised conditional level of significance for the 2× 2-table when testing the
equality of two probabilities, Statistica Neerlandica 24, 1–9 (1970).
126
[17] L. Ehwerhemuepha, H. Sok, and C. Rakovski, A more powerful unconditional exact test of
homogeneity for 2× c contingency table analysis, Journal of Applied Statistics , 1–11 (2019).
[18] A. L. Byrne, B. J. Marais, C. D. Mitnick, L. Lecca, and G. B. Marks, Tuberculosis and
chronic respiratory disease: a systematic review, International Journal of Infectious Diseases
32, 138–146 (2015).
[19] S. D. Kumbhare, T. Beiko, S. R. Wilcox, and C. Strange, Characteristics of copd patients us-
ing united states emergency care or hospitalization, Chronic Obstructive Pulmonary Diseases
3, 539 (2016).
[20] K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenk-
ins, R. Rodriguez-Roisin, C. Van Weel, et al., Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease: Gold executive summary, American
journal of respiratory and critical care medicine 176, 532–555 (2007).
[21] H. Wang, M. Naghavi, C. Allen, R. M. Barber, Z. A. Bhutta, A. Carter, D. C. Casey,
F. J. Charlson, A. Z. Chen, M. M. Coates, and Others, Global, regional, and national life
expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–
2015: a systematic analysis for the Global Burden of Disease Study 2015, The lancet 388,
1459–1544 (2016).
[22] A. A. Cruz, Global surveillance, prevention and control of chronic respiratory diseases: a
comprehensive approach (World Health Organization, 2007).
[23] P. G. J. Burney, J. Patel, R. Newson, C. Minelli, and M. Naghavi, Global and regional trends
in COPD mortality, 1990–2010, European Respiratory Journal 45, 1239–1247 (2015).
[24] M. I. Asher and P. Ellwood, The global asthma report 2014, (2014).
[25] N. Pearce, N. A\”\it-Khaled, R. Beasley, J. Mallol, U. Keil, E. Mitchell, and C. Robertson,
Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study
of Asthma and Allergies in Childhood (ISAAC), Thorax 62, 758–766 (2007).
[26] W. H. Organization, Global Asthma report 2013 (World Health Organization, 2013).
[27] G. D’Amato, C. Vitale, A. Molino, A. Stanziola, A. Sanduzzi, A. Vatrella, M. Mormile,
M. Lanza, G. Calabrese, L. Antonicelli, et al., Asthma-related deaths, Multidisciplinary res-
piratory medicine 11, 37 (2016).
[28] N. I. of Health et al., Global initiative for asthma, Global strategy for asthma management
and prevention. NHLBI/WHO work shop report (1995).
[29] G. A. Network et al., The global asthma report 2014, Auckland, New Zealand 769, 28–36
(2014).
[30] W. H. Organization, Global Asthma report 2014 (World Health Organization, 2014).
[31] T. Nurmagambetov, R. Kuwahara, and P. Garbe, The economic burden of asthma in the
United States, 2008–2013, Annals of the American Thoracic Society 15, 348–356 (2018).
127
[32] D. Beran, H. J. Zar, C. Perrin, A. M. Menezes, P. Burney, and Others, Burden of asthma
and chronic obstructive pulmonary disease and access to essential medicines in low-income
and middle-income countries, The Lancet Respiratory Medicine 3, 159–170 (2015).
[33] C. Troeger, B. Blacker, I. A. Khalil, P. C. Rao, J. Cao, S. R. M. Zimsen, S. B. Albertson,
A. Deshpande, T. Farag, Z. Abebe, and Others, Estimates of the global, regional, and na-
tional morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries,
1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, The Lancet
infectious diseases 18, 1191–1210 (2018).
[34] E. Keeler, M. D. Perkins, P. Small, C. Hanson, S. Reed, J. Cunningham, J. E. Aledort,
L. Hillborne, M. E. Rafael, F. Girosi, and Others, Reducing the global burden of tuberculosis:
the contribution of improved diagnostics, Nature 444, 49–57 (2006).
[35] J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M.
Parkin, D. Forman, and F. Bray, Cancer incidence and mortality worldwide: IARC Cancer-
Base No. 11 Lyon, France: International Agency for Research on Cancer (2013).
[36] S. M. Jeon, J.-W. Kwon, S. H. Choi, and H.-Y. Park, Economic burden of lung cancer: A
retrospective cohort study in South Korea, 2002-2015, PloS one 14 (2019).
[37] J. D. Ribeiro and G. B. Fischer, Chronic obstructive pulmonary diseases in children, Jornal
de pediatria 91, S11—-S25 (2015).
[38] C. Svanes, J. Sunyer, E. Plana, S. Dharmage, J. Heinrich, D. Jarvis, R. de Marco, D. Norbäck,
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